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ABSTRACT
The Effects of Alcohol on BDNF and CD5 Dependent Pathways
Andrew Jordan Payne
Neuroscience Center, Brigham Young University
Doctor of Philosophy
Alcohol represents the third leading cause of preventable death in the United States. Yet,
despite its prevalent role in impeding human health, there is much to understand about how it
elicits its effects on the body and how the body and brain change when an individual becomes
physiologically dependent upon alcohol. The work presented herein represents an effort to
elucidate the acute and chronic effects of alcohol on the nervous system. We investigate two
specific protein pathways and their role in alcohol’s effects on the body. The first begins with
brain-derived neurotrophic factor (BDNF), which acts on TrkB, and ends with KCC2. We
demonstrate that BDNF expression is increased in the VTA during withdrawal from chronic but
not acute alcohol exposure and that this increase persists for at least seven days. Concomitantly,
we demonstrate that the activation of GABAA channels on produces less inhibition of VTA
GABA neurons in mice treated with chronic intermittent ethanol exposure than in alcohol naïve
mice. This effect likewise persisted for at least seven days. We illustrate that BDNF has no
apparent direct effect on VTA GABA neuron firing rate. The second pathway begins with the T
cell marker CD5 and ends with the anti-inflammatory cytokine, IL-10. We demonstrate that in a
genetic CD5 knockout (CD5 KO) mouse model both alcohol consumption as well as the sedative
properties of alcohol are reduced. Since CD+ B cells secrete more IL-10 than CD5- B cells, we
also demonstrate the effects of IL-10 on VTA neurons. We show that IL-10 has direct effects on
VTA dopamine (DA) neurons by increasing their firing activity. We relatedly illustrate that IL10 produces an increase in DA release in the nucleus accumbens (NAc). However, contrary to
our hypotheses, we show that IL-10 produces conditioned place aversion rather than conditioned

place preference in a place conditioning paradigm, suggesting that IL-10 might mediate paininduced secretions of DA. Collectively, these results suggest two potential therapeutic targets to
reduce alcohol consumption that need further validation. They also suggest a novel mechanism
for the sedative effects of alcohol at moderate and high doses.

Keywords: alcohol, ethanol, addiction, dependence, BDNF, TrkB, KCC2, CD5, IL-10, cytokine,
VTA, GABA, NAc

ACKNOWLEDGEMENTS
I would like to acknowledge the contributions of my doctoral advisory committee in the
completion of this work. In particular, this work would have not been possible without the
efforts, guidance, and resources of my advisor, Dr. Scott Steffensen. Also, of notable mention
were the guidance and instruction of Dr. Jordan Yorgason and Dr. Kyle Bills. Many current and
former graduate students and undergraduate students at Brigham Young University have made
significant contributions, in particular those who are listed as authors on the manuscripts
highlighted here. Finally, and perhaps most importantly, the unending support of my wife, Dr.
Angela Payne, and family were of critical importance in the completion of the work contained
herein. As with any scientific accomplishment, this could not have been possible without the
contributions of many, and any credit merited by the information contained herein should be
distributed across the dozens who are responsible for generating these results.

TABLE OF CONTENTS

LIST OF FIGURES ....................................................................................................................... ix
LIST OF TABLES ...........................................................................................................................x
CHAPTER 1: INTRODUCTION ....................................................................................................1
Brain-derived Neurotrophic factor ...................................................................................... 2
Neuroimmune interactions .................................................................................................. 3
Manuscript One ................................................................................................................... 4
Manuscript Two .................................................................................................................. 5
Manuscript Three ................................................................................................................ 5
Manuscript Four .................................................................................................................. 6
CHAPTER 2: Ventral Tegmental Area GABA Neurons Are Resistant to
GABA(A) Receptor-mediated Inhibition During Ethanol Withdrawal ...........................................7
Abstract ............................................................................................................................... 8
Introduction ....................................................................................................................... 10
Materials and Methods ...................................................................................................... 12
Animal subjects ..................................................................................................................... 12
Chronic intermittent ethanol exposure to establish alcohol dependence ............................... 13
Drink-in-the-dark behavioral experiments ............................................................................ 13
Preparation of brain slices ..................................................................................................... 14
Cell-attached recording of spike activity in brain slices........................................................ 14
Drug preparation and administration ..................................................................................... 16
Statistical analyses ................................................................................................................. 16
Results ............................................................................................................................... 17
Sensitivity of VTA neuron firing rate to the GABA(A) receptor agonist muscimol ............ 17
Muscimol inhibition of VTA neuron firing rate after a single injection of ethanol .............. 19
Muscimol inhibition of VTA neuron firing rate after chronic ethanol .................................. 21
Discussion ......................................................................................................................... 26
Acknowledgements ........................................................................................................... 31
CHAPTER 3: BDNF levels increase in withdrawal from chronic alcohol
exposure: a potential mechanism for alcohol withdrawal..............................................................32
v

Abstract ............................................................................................................................. 33
Introduction ....................................................................................................................... 34
Brain-Derived Neurotrophic Factor....................................................................................... 35
Potassium-Chloride Cotransporter 2 (KCC2)........................................................................ 36
Combined Model ................................................................................................................... 37
Methods............................................................................................................................. 38
Animals .................................................................................................................................. 38
Drug Administration .............................................................................................................. 39
ELISA .................................................................................................................................... 39
Alcohol Consumption ............................................................................................................ 40
Chronic Intermittent EtOH .................................................................................................... 40
Immunohistochemistry .......................................................................................................... 41
RESULTS ......................................................................................................................... 42
BDNF and Pro-BDNF Expression in EtOH Withdrawal ...................................................... 42
Effects of BDNF on VTA GABA Neuron Firing Rate ......................................................... 43
Alcohol-induced Changes in KCC2 expression .................................................................... 44
Role of TrkB in EtOH seeking behavior ............................................................................... 46
Discussion ......................................................................................................................... 48
BDNF Expression .................................................................................................................. 48
VTA GABA Neuron Activity................................................................................................ 48
Changes in KCC2 Expression During Withdrawal from Chronic EtOH .............................. 49
Role of TrkB Receptors in EtOH Consumption .................................................................... 49
Conclusion ........................................................................................................................ 50
CHAPTER 4: CD5 knockout mice exhibit reduced sensitivity to the sedative
effects of alcohol and reduced alcohol seeking behavior ..............................................................52
Introduction ....................................................................................................................... 54
Methods............................................................................................................................. 56
Animal Subjects ..................................................................................................................... 56
Flow Cytometry ..................................................................................................................... 56
Locomotor Activity ............................................................................................................... 57
Loss of Righting Reflex......................................................................................................... 57
Two Bottle Choice Drinking ................................................................................................. 58
vi

Fast Scan Cyclic Voltammetry .............................................................................................. 58
Single-Unit Recordings ......................................................................................................... 59
Results ............................................................................................................................... 60
Knockout Characterization .................................................................................................... 60
Alcohol-Induced Sedation ..................................................................................................... 61
Ethanol Consumption ............................................................................................................ 64
Spontaneous Dopamine Release ............................................................................................ 65
Ethanol Effects on VTA GABA Neurons in CD5 KO Mice ................................................. 65
Discussion ......................................................................................................................... 68
Alcohol-Induced Sedation ..................................................................................................... 68
Ethanol Consumption ............................................................................................................ 69
Ethanol Effects on GABA Neuron Inhibition ....................................................................... 70
CHAPTER 5: Interleukin-10 effects on VTA neurons ..................................................................72
Abstract ............................................................................................................................. 73
Introduction ....................................................................................................................... 74
Methods............................................................................................................................. 75
Animal Subjects ..................................................................................................................... 75
Preparation of Brain Slices .................................................................................................... 75
Electrophysiology Recordings in Brain Slices ...................................................................... 76
Ex Vivo Voltammetry ........................................................................................................... 77
Microdialysis and High Performance Liquid Chromatography ............................................ 78
Conditioned Place Preference Procedure .............................................................................. 79
Statistical Analyses ................................................................................................................ 80
Results ............................................................................................................................... 81
IL-10 Modulates the Firing Rate of VTA Neurons ............................................................... 81
Effects of IL-10 on Optogenetically-Evoked IPSCs on VTA DA Neurons .......................... 82
Effects of IL-10 on mIPSCs on VTA DA Neurons ............................................................... 83
PI3K Inhibitor Blocks IL-10 Effects ..................................................................................... 84
Effects of IL-10 on DA Release in the NAc .......................................................................... 85
Effects of IL-10 on Conditioned Place Preference ................................................................ 86
Discussion ......................................................................................................................... 87
vii

Cytokine Effects on VTA Neuron Firing Rate ...................................................................... 87
Effects of IL-10 on Synaptic Transmission ........................................................................... 88
IL-10 Increases DA Release .................................................................................................. 89
CHAPTER 6: CONCLUSION ......................................................................................................91
Manuscript One ................................................................................................................. 91
Manuscript Two ................................................................................................................ 92
Manuscript Three .............................................................................................................. 93
Manuscript Four ................................................................................................................ 94
REFERENCES ..............................................................................................................................96

viii

LIST OF FIGURES
Figure 2-1: Comparison of the sensitivity of VTA GABA vs DA neurons to muscimol inhibition
of firing rate .................................................................................................................................. 18
Figure 2-2: Decreased sensitivity of VTA GABA neurons to muscimol 24 hrs after a single
injection of ethanol ....................................................................................................................... 20
Figure 2-3: Decreased sensitivity of VTA GABA neurons to muscimol after chronic ethanol
injections ....................................................................................................................................... 22
Figure 2-4: Drink-in-the-dark model of alcohol dependence ....................................................... 24
Figure 2-5: Decreased sensitivity of VTA GABA, but not DA neurons, to muscimol after chronic
intermittent ethanol vapor exposure.............................................................................................. 25
Figure 3-1: The circuit of interest ................................................................................................. 34
Figure 3-2: A representation of the current working model for alcohol dependence ................... 38
Figure 3-3: BDNF expression in the VTA (Left) and NAc (Right) of mice exposed to acute vs.
chronic ethanol, including time points at 1 day of withdrawal and at 7 days of withdrawal ....... 42
Figure 3-4: Firing rate of VTA GABA neurons is not impacted by acute superfusion of BDNF 43
Figure 3-5: Fluorescence imaging of brain slices ......................................................................... 44
Figure 3-6: Immunohistochemistry group means in the ventral tegmental area (VTA) and nucleus
accumbens (NAc).......................................................................................................................... 45
Figure 3-7: Drinking behavior as measured by two bottle choice, showing an increase in drinking
behavior in the EtOH exposed mice with no increase in the air exposed mice ............................ 46
Figure 3-8: Alcohol consumption in response to CIE and TrkB drugs ........................................ 47
Figure 4-1: CD5 Knockout (KO) mice exhibit a lack of CD5 expression.................................... 60
Figure 4-2: CD5 KO mice have lower baseline locomotor activity ............................................. 61
Figure 4-3: CD5 KO mice have blunted EtOH reduction to locomotor activity .......................... 62
Figure 4-4: CD5 KO mice show reduced EtOH sedation (Preliminary) ...................................... 63
Figure 4-5: CD5 KO mice drink less ethanol than wildtype controls........................................... 64
Figure 4-6: CD5 KO mice do not differ from WT controls on spontaneous DA release ............. 65
Figure 4-7: CD5 KO mice do not differ from WT controls in basal firing rate or EtOH dependent
firing rate reduction....................................................................................................................... 67
Figure 5-1: Effects of IL-10 on VTA Neuron Firing Rate............................................................ 81
Figure 5-2: Effects of IL-6 on VTA Neuron Firing Rate.............................................................. 82
Figure 5-3: Effects of IL-10 on Optogenetic IPSCs on VTA DA Neurons .................................. 83
Figure 5-4: Effect of IL-10 on mIPSCs in VTA DA Neurons ...................................................... 84
Figure 5-5: Effects of IL-10 on Evoked DA Release in the NAc Ex Vivo Using Fast Scan Cyclic
Voltammetry ................................................................................................................................. 85
Figure 5-6: Microinjections of IL-10 enhance DA release in the NAc ........................................ 86
Figure 5-7: ICM administration of IL-10 produced conditioned place aversion .......................... 87

ix

LIST OF TABLES
Table 1: Breakdown of the number of animals, tracts, and neurons recorded by group. ............. 66

x

CHAPTER 1: INTRODUCTION
For thousands of years men and women have consumed alcohol (McGovern et al., 2004).
The reasons for this behavior are distinct and varied and can range from the quest for pleasure to
a desire to escape one’s problems, from a social lubricant to a physiological dependence.
Whatever the reason for beginning or continuing to drink, the long-term impact is clear: alcohol
destroys. In 2000, alcohol use was the cause of approximately 85,000 annual deaths in the
United States, which makes it the third leading cause of preventable death, trailing only behind
tobacco use and poor diet and physical inactivity (Mokdad et al., 2005). That is an average of
over 230 fatalities per day or roughly 1 life lost every 6 minutes. Economically, the impact of
alcohol is tremendous. It has been estimated that alcohol use alone causes a $249 billion burden
to our economy (Sacks et al., 2015). For sake of reference, as of the end of Q1 2020, the annual
gross domestic product (GDP) of the United States was $21.54 trillion, which means that the
economic cost of alcohol can be measured on the order of magnitude of a whole percentage point
of the country’s entire GDP (Gross Domestic Product, 1st Quarter 2020 (Third Estimate);
Corporate Profits, 1st Quarter 2020 (Revised Estimate), 2020). Saying that the economic cost of
alcohol use is tremendous is an understatement.
In addition to the economic and health impact of alcohol, it takes an immeasurable toll on
families and individuals. It destroys marriages and careers, relationships, and lives, and there
doesn’t seem to be an end in sight. It is for this exact reason that we research alcoholism. The
current treatments for alcoholism have a lackluster success rate, and relapse rates can exceed
50% in the first year after treatment (Miller et al., 2001). On top of that, according to the
National Institutes of Health, less than 8% of adults who had alcohol use disorder (AUD)
received treatment (Alcohol Facts and Statistics, 2020). Indeed, we need better treatments for
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alcoholism, and perhaps the best way to approach finding better treatment options is to better
understand how alcohol works.
In spite of the fact that alcohol has been consumed for millennia and modern researchers
have sought to understand alcohol’s effects on the brain and body for decades, we are still left
with many unanswered questions about the mechanisms by which alcohol produces its effects on
the body. With many drugs of abuse, a mechanism of action becomes quite clear, but with
alcohol we have observed many small effects throughout the body with nothing we could call a
“smoking gun” to tell us how alcohol produces euphoria at low doses, sedation at high doses, and
dependence with repeated doses. That is the impetus behind this work. We aim to better
understand the mechanisms of action of alcohol acutely and chronically. It is our hope that by
doing so we can uncover novel targets for new therapeutics that can improve the success of
alcoholism treatment. We have undertaken to accomplish this by investigating two specific
molecular pathways.
Brain-derived Neurotrophic factor
The first pathway is initiated by increased secretions of brain-derived neurotrophic factor
(BDNF) in the ventral tegmental area (VTA). While BDNF is usually responsible for protective
and restorative functions in the brain, we hypothesize that in the case of alcohol dependence,
BDNF is at the inception of maladaptive processes that lead to dependence and/or withdrawal.
The main receptor for BDNF in the brain is tyrosine receptor kinase B (TrkB). We believe that
increases in BDNF expression lead to an increase in TrkB activity in the VTA and that this is the
foundation of hyperactive inhibitory pathways that result in decreased dopamine (DA) release
during withdrawal. It has been shown in the hippocampus that the activation of TrkB can induce
a decrease in the expression of the potassium chloride cotransporter 2 (KCC2). Since the
2

primary function of KCC2 is to export from the cell the chloride that is ingested through normal
inhibitory activity at γ-aminobutyric acid (GABA) synapses, a decrease in expression of KCC2
would naturally result in a rise of intracellular chloride levels, which would significantly disrupt
the normal inhibitory activity of GABA type A (GABAA) channels. This would logically lead to
an increase in activity of any neuron where this change in KCC2 expression had occurred. We
hypothesize that this is transpiring in GABA neurons in the VTA and that these neurons then
become hyperexcitable. We anticipate that this chain of events is thereby inhibiting the activity
of VTA DA neurons, making them less active and reducing the release of DA in the nucleus
accumbens (NAc). The release of DA in the NAc has long been thought to be correlated with
reward and reinforcement. Recent additions to the peer-reviewed literature have refined that
view to include learning signals and reward prediction error as well as other factors that we will
not discuss here, but suffice it to say that relegating the role of DA in the NAc to reward is a bit
too simplistic. However, DA release in the NAc that is initiated in the VTA is still strongly
implicated in reinforcement and addiction pathways, and as such is a critical to our
understanding of alcoholism.
Neuroimmune interactions
The second pathway is related to neuroimmune interactions. It has been suggested that
the nervous system and the immune system are tightly intertwined in various ways. For
example, several studies have been conducted to investigate the impact of cytokines of the brain.
We will present here the results of one such study conducted in our lab. Although it might seem
improbable upon first hearing, the base of evidence supporting connections between the nervous
system and the immune system continues to increase.
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We hypothesized that the T cell marker, cluster of differentiation 5 (CD5), plays a role in
alcohol reward and/or dependence. There is evidence that CD5 is involved in synaptogenesis
during development, particularly on GABA neurons (Brask et al., 2004; Fujita et al., 2017; Kim
et al., 2002). Additionally, CD5 seems to be a factor in the production and/or release of the antiinflammatory cytokine interleukin-10 (IL-10). Immune B cells that are positive for CD5 release
more IL-10 than B cells that are negative for CD5 (Gary-Gouy et al., 2002). Additionally, the
soluble form of CD5 can bind IL-6, which we explored in connection with VTA cellular
dynamics as well (Aparicio-Siegmund et al., 2017).
The structure of this work will deviate from the traditional dissertation in that each
chapter represents a manuscript prepared for or published in a scientific journal. The format will
be consistent with the journal to which the manuscript will be or has been submitted. In total we
will highlight four manuscripts: two related to the BDNF pathway and two related to the
CD5/IL-10 pathway. The level of contributions for each work are represented by their respective
author lists.
Manuscript One
The first manuscript tests the hypothesis that GABA switching occurs with chronic
alcohol exposure. We define GABA switching as the phenomenon described above where
chloride buildup inside the cell causes the inhibitory GABAA channels to become less effective
and even tend toward becoming excitatory. We utilize cell-attached patch clamp
electrophysiology and the GABAA agonist muscimol to test this hypothesis. We generate what
is sometimes called a muscimol sensitivity curve, which is essentially a dose response curve that
illustrates the concentrations at which muscimol is effective at inhibiting neuronal activity. We
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test these effects in animals that are alcohol naïve and alcohol dependent to assess the chronic
effects of alcohol on chloride dynamics.
Manuscript Two
The second manuscript tests the hypothesis that this GABA switching is mediated by the
BDNF/TrkB/KCC2 pathway described above. We utilize an enzyme-linked immunosorbent
assay (ELISA) to evaluate the expression level of BDNF in the VTA and NAc of animals that
are acutely exposed to alcohol, chronically exposed to alcohol, and naïve to alcohol. We use
cell-attached patch clamp electrophysiology and the TrkB antagonist ANA-12 to ascertain
whether BDNF has any direct effects on VTA GABA neuron activity. We utilize
immunohistochemistry (IHC) staining to investigate the expression patterns of KCC2 in animals
that are alcohol naïve and alcohol dependent as well as how the TrkB drugs ANA-12 and 7,8DHF affect this expression pattern. Lastly, we utilize a drinking in the dark binge drinking
paradigm to evaluate the impact of ANA-12 and 7,8-DHF on alcohol seeking behavior in naïve
and dependent animals.
Manuscript Three
The third manuscript tests the hypothesis that the presence of CD5 impacts alcohol
seeking behavior as well as alcohol-induced sedation. For this study, a CD5 knockout mouse
(CD5 KO) was used and validated with flow cytometry to ensure that CD5 was not present in the
knockout population. We utilized a 24-hour access two bottle choice drinking paradigm to
measure alcohol seeking behavior and used an open field behavioral assay as well as a loss of
righting reflex assay to measure the sedative properties of alcohol. We also measured the
activity of GABA neurons using an in vivo single unit measurement technique to determine
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whether CD5 had any impact on the baseline activity of GABA neurons in the VTA and
measured spontaneous DA release in the NAc.
Manuscript Four
The fourth manuscript tests the hypothesis that the anti-inflammatory cytokine IL-10 and
the pro-inflammatory cytokine IL-6 affect the activity of VTA neurons. We use patch clamp
electrophysiology to examine the effect that IL-10 and IL-6 have on the firing rate of VTA
GABA and DA neurons in a slice preparation. This same preparation allows us to investigate the
effects of IL-10 on optogenetically stimulated inhibitory post-synaptic currents (oIPSCs) and
miniature IPSCs. We also use in vivo microdialysis and ex vivo voltammetry to investigate the
effect of IL-10 on DA release in the NAc. Lastly, we use a place conditioning paradigm to
examine whether IL-10 is, of itself, rewarding when administered directly into the cerebrospinal
fluid.
Taken together, we anticipate that the results from these studies will provide evidence of
novel mechanisms of the rewarding and sedating effects of alcohol. Future work to validate the
involvement of KCC2 in alcohol seeking behavior as well as elucidating CD5 and/or IL-10 as
potential drug targets will continue to validate these mechanisms and move toward the potential
of drug development.
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CHAPTER 2: Ventral Tegmental Area GABA Neurons Are Resistant to GABA(A) Receptormediated Inhibition During Ethanol Withdrawal

Nelson AC, Williams SB, Pistorius SS, Park HJ, Woodward TJ, Payne AJ, Obray
JD, Shin SI, Mabey JK, Steffensen SC*

Department of Psychology and Center for Neuroscience. Brigham Young University, Provo,
Utah 84602

*Corresponding author: Scott C. Steffensen (Scott_Steffensen@byu.edu)

Acknowledgements: This work was supported by NIH grants AA020919 and DA035958 to SCS.
This article was published in Frontiers in Neuroscience in 2018 under a Creative Commons
Attribution License. I hereby confirm that the use of this article is compliant with all publishing
agreements. The proper reference for attribution is below.

Nelson AC, Williams SB, Pistorius SS, et al. Ventral Tegmental Area GABA Neurons Are
Resistant to GABA(A) Receptor-Mediated Inhibition During Ethanol Withdrawal. Front
Neurosci. 2018;12:131. Published 2018 Mar 5. doi:10.3389/fnins.2018.00131

Keywords: ventral tegmental area, GABA(A) receptor, alcohol, VTA GABA neurons,
NMDA receptors, withdrawal, inhibition, adaptation, resistance

7

Abstract
The neural mechanisms underlying alcohol dependence are not well understood. GABAergic
neurons in the ventral tegmental area (VTA) are a relevant target for ethanol. They are inhibited
by ethanol at physiologically relevant levels in vivo and display marked hyperexcitability during
withdrawal. In the present study, we examined the effects of the GABA(A) receptor agonist
muscimol on VTA neurons ex vivo following withdrawal from acute and chronic ethanol
exposure. We used standard cell-attached mode electrophysiology in the slice preparation to
evaluate the effects of muscimol on VTA GABA neuron firing rate following exposure to acute
and chronic ethanol in male CD-1 GAD-67 GFP mice. In the acute condition, the effect of
muscimol on VTA neurons was evaluated 24 hrs and 7 days after a single in vivo dose of saline
or ethanol. In the chronic condition, the effect of muscimol on VTA neurons was evaluated 24
hrs and 7 days after either 2 weeks of twice-daily IP ethanol or saline or following exposure to
chronic intermittent ethanol (CIE) vapor or air for 3 weeks. VTA GABA neuron firing rate was
more sensitive to muscimol than DA neuron firing rate. VTA GABA neurons, but not DA
neurons, were resistant to the inhibitory effects of muscimol recorded 24 hours after a single
ethanol injection or chronic ethanol exposure. Administration of the NMDA receptor antagonist
MK-801 before ethanol injection restored the sensitivity of VTA GABA neurons to muscimol
inhibition. Seven days after ethanol exposure, VTA GABA neuron firing rate was again
susceptible to muscimol’s inhibitory effects in the acute condition, but the resistance persisted in
the chronic condition. These findings suggest that VTA GABA neurons exclusively undergo a
shift in GABA(A) receptor function following acute and chronic exposure. There appears to be
transient GABA(A) receptor-mediated plasticity after a single exposure to ethanol that is
mediated by NMDA glutamate receptors. In addition, the resistance to muscimol inhibition in
VTA GABA neurons persists in the dependent condition, which may contribute to the
8

hyperexcitability of VTA GABA neurons and inhibition of VTA DA neurons during withdrawal
as well as the motivation to seek alcohol.
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Introduction
Alcoholism is a chronic relapsing disorder that has an enormous impact on society. A
major goal of research on alcoholism is to characterize the critical neural substrates that are most
sensitive to alcohol, adapt in association with chronic consumption and drive subsequent
alcohol-seeking behavior. The mesocorticolimbic dopamine (DA) system originating in the
ventral tegmental area (VTA) of the midbrain and projecting to the nucleus accumbens (NAc) is
known to be involved in reward. The emerging view is that the dysregulated homeostasis that
accompanies the development of drug addiction may result from experience-dependent
neuroadaptations that hijack normal synaptic transmission in this system (Hyman & Malenka,
2001; Hyman et al., 2006; Kauer & Malenka, 2007; Nugent & Kauer, 2008).
The VTA is highly involved in adaptive reward and motivation processing and is
composed of DA (65%), γ-aminobutyric acid (GABA; 30%), and glutamate (GLU; 5%) neurons
(Dobi et al., 2010). Both in vivo (Gessa et al., 1985) and in vitro (Brodie & Appel, 1998; Brodie
et al., 1990) electrophysiological studies indicate that acute ethanol increases VTA DA neuron
firing rate (EC50 of 120 mM in the slice) and DA release in limbic structures (Imperato & Di
Chiara, 1986), and that withdrawal from chronic ethanol reduces DA firing rate and release in
the NAc (Diana et al., 1993). Although the release of DA in the NAc positively reinforces drug
use, it has been suggested that the changes in DA are strongly regulated by VTA GABA neurons
(Bocklisch et al., 2013; Nugent & Kauer, 2008; Steffensen et al., 2011; Ting & van der Kooy,
2012). GABAergic projections to the VTA come from several regions including the NAc, rostromedial tegmentum, and the ventral pallidum, but another major inhibitory regulation of VTA DA
and GABA neurons is by GABAergic interneurons within the VTA (Johnson & North, 1992;
Steffensen et al., 1998). In support of this, results from studies in Cre mice [GAD-Cre (Tan et al.,
2012) or VGAT-Cre (van Zessen et al., 2012)] expressing channel rhodopsin-2 show that
10

selective activation of VTA GABA neurons by light stimulation inhibits DA neuron activity,
inducing conditioned place aversion (Tan et al., 2012) and disrupting reward consumption (van
Zessen et al., 2012). In contrast, silencing the activity of VTA GABA neurons by expressing the
proton pump halorhodopsin in VTA GABA neurons disinhibits DA neurons (Bocklisch et al.,
2013). We have shown in multiple reports that acute ethanol inhibits the firing rate of VTA
GABA neurons in rats with an IC50 of 1.0 g/kg (Gallegos et al., 1999; Ludlow et al., 2009;
Steffensen et al., 2009; Stobbs et al., 2004), which is one order of magnitude more sensitive than
ethanol effects on DA neurons (Brodie & Appel, 1998; Gysling & Wang, 1983; Mereu et al.,
1987). VTA GABA neurons are even more sensitive to ethanol in C57BL/6 and CD-1 mice, as
they are inhibited with an IC50 of 0.25 g/kg (Steffensen et al., 2011). Of most relevance to this
study, VTA GABA neurons recorded in vivo become hyperexcitable (firing rates averaging >100
Hz) during withdrawal from ethanol and tolerance accrues to ethanol inhibition of VTA GABA
neuron firing rate (Gallegos et al., 1999). Thus, VTA GABA neurons undergo pronounced
adaptation during withdrawal from chronic ethanol.
We have shown in multiple reports that GABA(A) receptors [GABA(A)Rs] switch their
function during opiate dependence (Laviolette et al., 2004; Ting et al., 2013; Vargas-Perez et al.,
2014; Vargas-Perez, Kee, et al., 2009). The functional switch results from increased levels of
brain-derived neurotrophic factor (BDNF), which activates the high-affinity tyrosine kinase B
(TrkB) receptor (Vargas-Perez, Kee, et al., 2009), which is expressed in VTA GABA neurons
(Numan et al., 1998). Ethanol withdrawal not only produces adaptations in VTA GABA neurons
(Gallegos et al., 1999), but also GABA(A)R subunit composition in the VTA and the
hippocampus (Cagetti et al., 2003; Charlton et al., 1997), and it is reasonable to assume that
these changes are important for precipitating this switch in the neurobiological substrates
mediating ethanol reinforcement. Considerable evidence suggests that activation of GABA(A)R
11

complexes can produce depolarization in lieu of its more traditional hyperpolarizing response
(Coull et al., 2003; Hubner et al., 2001; Kaila et al., 1993; Rivera et al., 1999; Staley et al.,
1995). The switching of GABA(A)R functionality occurs during development and under
pathological conditions like epilepsy. There is a major gap in our understanding of the neural
substrates that adapt with alcohol dependence, and whether or not they are causal or reflective.
Thus, the aim of this study was to evaluate GABA(A)R function in VTA GABA neurons during
withdrawal from acute and chronic ethanol. We hypothesized that, similar to what we have
reported with opiate dependence, VTA GABA neuron GABA(A)R sensitivity to the GABA(A)R
agonist muscimol would adapt to chronic ethanol, reflecting a functional shift of the receptors
and VTA GABA neurons themselves during withdrawal.
Materials and Methods
Animal subjects
Male glutamate-decarboxylase-67 (GAD-67) green fluorescent protein (GFP) knock-in
CD-1 (white albino) mice (Tamamaki et al., 2003) were bred and cared for in accordance with
the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals. For
each methodology employed, animals were treated in strict accordance with the Brigham Young
University Animal Research Committee (IACUC) guidelines, which reviewed and approved the
procedures detailed herein. Once weaned at post-natal day 21, all mice were housed in maximum
groups of four and given ad libitum access to solid food and water and placed on a reverse
light/dark cycle with lights ON from 8 PM to 8 AM. Any mice used in injection experiments
were briefly (2-5 min) anesthetized with isoflurane to reduce the stress of the injection and allow
for administration of large volumes, and injected intraperitoneally (IP) with a sterile needle.
Animals returned to their home cages 30 minutes following an injection.
12

Chronic intermittent ethanol exposure to establish alcohol dependence
Animals were made dependent on ethanol in one of two methods of chronic intermittent
ethanol (CIE) exposure, either by multiple injections or in vapor chambers. In the multiple
injections method, mice were injected IP with ethanol (3.0 g/kg) or saline twice-daily for 14
days, which was sufficient to establish dependence, as we have reported previously (Gallegos et
al., 1999). However, no attempt was made in injection studies to determine dependence (i.e.
increased drinking). In the vapor chamber method, ethanol vapor was used to establish ethanol
dependence. We modified the vapor chamber system developed in the lab of Graeme Mason at
Yale (Wang et al., 2012). The six automated chamber system consisted of an air-pressurized,
feedback-controlled ethanol flask with flow valves to each of three sealed chambers to regulate
the flow of air (11 L/min) and concentration of alcohol to three of six chambers placed in a
ventilation hood. A breathalyzer (Drager Alcotest 6510) was used in a feedback loop to regulate
the concentration of ethanol. In order to avoid overdosing the first week of CIE vapor exposure,
mice were exposed to 4, 6, and 8 hrs of vapor before exposing to 16 hrs vapor/day. Control
animals were housed in three sealed chambers in the same ventilation hood, but only received
air. Blood alcohol levels (BALs) were measured using an enzymatic kit (Sigma-Aldrich, St.
Louis, MO). Even at the 5 L/min feedback flowmeter level the air-exposed mice did not show
any detectable alcohol above the 1 mg% detection limit of the breathalyzer or the BAL
determination method.
Drink-in-the-dark behavioral experiments
To observe a behavioral correlate of alcohol dependence and validate our vapor chamber
method, mice were trained and evaluated in a drink-in-the-dark (DID) two-bottle choice alcohol
drinking test. Mice were exposed to CIE vapor or air for 3 weeks, as described above. After a
withdrawal period of 24 hours, animals were removed from home cages three hours into the dark
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cycle and placed individually in cages with the bedding and food removed. They were given two
sipper tubes, with one containing tap water and the other containing tap water and ethanol (20%
v/v). Mice were allowed to drink from the tubes for 2 hours in the dark and were then returned to
their home cages. They repeated this test over 5 consecutive days with no CIE vapor or air
exposure during that time. Animals then underwent 3 days of withdrawal and had a one-day
challenge DID session on day 9 with identical conditions.
Preparation of brain slices
All brain slice preparations were performed in P18-120 day old GAD-67 GFP CD1 mice
in order to visualize GAD-67+ neurons in the VTA by GFP imaging. P18-28 day old mice were
used in the naïve experiments (see results below) only. Ethanol was only administered in animals
older than day P28. All mice used in ethanol exposure groups were age-matched and were P28120 days old with a median age at day P55. There was no effect of age on any results in this
study. Brains were rapidly extracted under isoflurane anesthesia. Upon extraction, the brain was
glued onto a cutting stage. The brain was then sectioned in ice-cold cutting solution (in mM: 194
Sucrose, 30 NaCl, 4.5 KCl, 1 MgCl2, 26 NaH2CO3, 1.2 NaH2PO4, 10 Glucose) bubbled with
95 % O2 / 5 % CO2. Targeting the VTA, 210 μm thick horizontal slices were sectioned on a
vibratome and then placed in an incubation chamber containing artificial cerebral spinal fluid
(ACSF; in mM: 124 NaCl, 3 KCl, 1.25 NaH2PO4, 26 NaHCO3, 12 glucose, 1.5 MgSO4, 2 CaCl2)
bubbled with 95 % O2 / 5 % CO2. After a recovery period of at least 30 minutes, brain slices
were placed in a recording tissue chamber with ACSF continuously flowing at 35 °C.
Cell-attached recording of spike activity in brain slices
Cell-attached mode studies used electrodes pulled from borosilicate glass capillaries (2.56 MΩ) and then filled with a NaCl solution containing (in mM) 124 NaCl, 2 KCl, 1.25
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NaH2PO4, 26 NaHCO3, 1.2 MgSO4, 2 CaCl2 adjusted to pH 7.4 with KOH. GABA neurons were
identified by fluorescence in GAD-67 GFP mice. Fluorescent cells were imaged on a Nikon
Eclipse FNI microscope with a 40x/0.80 n.a. objective lens. The filter cube for GFP detection
was a Nikon C-FL ENDOW GFP 96343 cube (Bandpass: 450-490 nm; Barrier: 500-550 nm;
dichroic: 495 nm). Excitation was performed with a Sutter Lambda TLED transmitted light
source at 506 nm. Cells were then imaged using differential interference contrast imaging in
order to facilitate cell attached recordings. Neurons that did no fluoresce and were characterized
by relatively slow, regular firing activity were assumed to be DA neurons. Positive pressure was
applied to the electrode when approaching the neuron. By applying suction to the electrode, a
seal (10 MΩ – 1 GΩ) was created between the cell membrane and the recording pipette.
Spontaneous spike activity was then recorded in cell-attached mode with an Axon Instruments
Multiclamp 700B amplifier, sampled at 10 kHz using an Axon 1440A digitizer, and collected
and analyzed using pClamp10 software. Neurons were not clamped throughout these
experiments although recorded in voltage clamp mode (voltage-clamp was set to 0 mV). Firing
rate recordings in this study were performed in cell-attached mode in order to avoid dialysing the
contents of the cells and disrupting the cytoplasmic milieu (e.g. the Cl- ion gradient), which we
have shown previously is perturbed with opiate dependence (Ting et al., 2013; Vargas-Perez et
al., 2014). A stable baseline recording of firing activity was obtained for 5-10 min before adding
drugs. Neurons that did not achieve a stable baseline firing rate during this time were rejected
from the study. Muscimol (0.01, 0.1, 1.0, 10.0 µM) in ACSF was perfused in successive doses
for 3-5 minutes at each dose until the neuron stopped firing. ACSF was then applied for 10
minutes. On a given experimental day, 2-3 horizontal slices containing the VTA were sectioned
from a mouse. VTA neurons were recorded and analyzed with at least 4 mice/group.
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Drug preparation and administration
Muscimol (Sigma-Aldrich) was solubilized in ACSF and superfused on brain slices at
0.01, 0.1, 1.0, and 10.0 µM. Drugs used for injections were solubilized in sterile 0.9 % saline and
injected IP: Ethanol (16% v/v solution; 3.0 or 4.0 g/kg) and MK-801 (0.5 mg/kg; Sigma-Aldrich,
St. Louis, MO).
Statistical analyses
For neuronal firing rate, results are presented as percent of baseline firing rate ± standard
error of the mean (SEM). Statistical significance required ≥ 95 % level of confidence (p ≤ 0.05).
Firing rate was analyzed for two min (baseline) before muscimol perfusion and for two minutes
at the end (peak effect) of the drug application, or the last two minutes before any drug was
applied. For comparison between groups, a mixed model ANOVA was used. Values were
Greenhouse-Geisser corrected for sphericity. Data was found to be reasonably distributed using
the Wilks-Shapiro test of normality. Using the criterion of median plus or minus 3 interquartile
range (IQR) outlying data points were identified. After determining that the outliers were not due
to data input error they were bounded to the median ± 3 IQR for analysis purposes. A priori
hypothesis testing was accomplished with Bonferroni correction post-hoc tests. Analysis
software included Minianalysis (Synaptosoft, Decatur, GA), Clampfit (Molecular Devices,
Sunnyvale, CA), Microsoft Excel, STATA (StataCorp, College Station, TX), and Igor Pro
(Wavemetrics, Oswego, OR). Significance levels were indicated on graphs with asterisks
*,**,***, corresponding to significance levels p<0.05, 0.01 and 0.001, respectively. Figures were
constructed with Igor Pro software.
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Results
Sensitivity of VTA neuron firing rate to the GABA(A) receptor agonist muscimol
We have previously shown that VTA GABA neurons are sensitive to the GABA(A)R
agonist muscimol at sub-micromolar concentrations (Ting et al., 2013; Vargas-Perez et al.,
2014). We present data on firing rate of putative VTA DA neurons along with VTA GABA
neurons in GAD-67 GFP mice. Neurons in the VTA of GAD-67 GFP mice that did not exhibit
fluorescence, but were characterized by relatively slow, regular firing activity, were presumed to
be DA neurons. The firing rate of VTA GABA neurons in ethanol-naïve animals was
significantly faster than putative VTA DA neurons (F(1, 35) = 18.91, p = 0.0001; GABA neurons
= 12.9 ± 2.0 Hz vs DA neurons = 4.8 ± 0.9 Hz; n=14, 7). We evaluated the effects of muscimol
on VTA neuron firing rate at concentrations ranging from 0.01 – 10.0 µM. Muscimol dosedependently reduced the firing rate of all neurons tested (F(4, 55) = 36.56, p < 0.0001). As
reported previously (Ting et al., 2013; Vargas-Perez et al., 2014), superfusion of muscimol
inhibited VTA GABA neuron firing rate with an IC50 < 0.1 µM (Fig. 1A). However, muscimol
inhibited VTA DA neuron firing rate with an IC50 > 1.0 μM (Fig. 1B). In ethanol naïve mice,
VTA GABA neurons were significantly more sensitive than VTA DA neurons to muscimol in
the 0.1 – 10 μM range (Fig. 1C; F(4, 55) = 3.76, p = 0.0090). A priori hypothesis testing with
Bonferroni correction revealed that GABA neuron firing rate was more depressed than DA
neuron firing rate by 0.1 μM muscimol (F(1, 90) = 15.36, p = 0.001) and 1.0 μM muscimol (F(1, 90)
= 22.42, p < 0.001; 0.01 μM: n=10, 7; 0.1 μM: n=10, 7; 1.0 μM: n=13, 6; 10.0 μM: n=10, 5).
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Figure 2-1: Comparison of the sensitivity of VTA GABA vs DA neurons to muscimol inhibition of
firing rate. (A) This representative VTA GABA neuron had a baseline firing rate of
approximately 10 Hz. The GABA(A)R agonist muscimol mildly inhibited the firing rate of this
neuron at 0.01 µM, moderately inhibited it at 0.1 µM, and abolished its activity at 1.0 µM. Insets
a,b are 5 sec traces of GABA neuron spike activity recorded at the times indicated on the graph.
(B) The ratemeter shows the activity of a representative VTA DA neuron, which had a baseline
firing rate of approximately 4 Hz. Muscimol had little or no effect on this DA neuron until the
firing rate was suppressed at 10.0 µM. Insets a,b are 5 sec traces of DA neuron spike activity
recorded at the times indicated on the graph. (C) The firing rate of VTA GABA neurons was
significantly more sensitive than VTA DA neurons to muscimol at 0.1 and 1.0 µM. Asterisks ***
represent significance levels p<0.001.
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Muscimol inhibition of VTA neuron firing rate after a single injection of ethanol
Firing rate was recorded in VTA GABA and DA neurons 24 hours after acute saline or
ethanol administration (non-dependent condition; Fig. 2A,B). GAD-67 GFP mice were
administered saline or 4.0 g/kg ethanol IP, which produced sedation for 1-2 hr with complete
recovery in all mice. In a subset of mice, the NMDA antagonist MK-801 (0.5 mg/kg) was
administered IP 15 minutes before ethanol or saline. There was no significant difference in
baseline firing rate between any of the acute treatment groups (F(3, 37) = 1.786, p = 0.167; Fig.
2A-C). Muscimol depressed VTA GABA firing rate in a dose dependent manner (F(4, 119) =
60.76, p < 0.0001; Fig. 2A-C). Acute withdrawal from a single exposure of ethanol altered the
response of VTA GABA neurons to muscimol (F(15, 119) = 3.69, p = 0.001; Fig. 2B-C). Posthoc
analysis with Bonferroni correction revealed that muscimol suppressed VTA GABA neuron
firing rate more in 7 day ethanol withdrawn mice than in 24 hour withdrawn mice (t(166) = 3.81, p
= 0.008; Fig. 2C) or MK-801 pretreated control mice (t(166) = -3.79, p = 0.008). VTA GABA
neuron firing rate in 24 hour withdrawn ethanol mice was less sensitive to muscimol depression
of firing rate than saline mice at 0.1 μM muscimol (t(166) = 3.95, p = 0.004). At 1.0 μM
muscimol, MK-801 pretreated control mice were less sensitive to muscimol inhibition of GABA
neuron firing rate than MK-801 pretreated ethanol withdrawn mice (t(166) = 4.01, p = 0.004; n=8
each), 7 day withdrawn ethanol-injected mice (t(166) = -4.08, p = 0.004; n=8 each), or salineinjected mice (t(166) = -4.39, p < 0.004; n=8 each). Specifically at 0.1 μM muscimol, VTA GABA
neuron firing was affected more by muscimol in 7 day withdrawn mice from a single ethanol
injection than in MK-801 (0.5 mg/kg IP administered 15 min prior to ethanol or saline)
pretreated 24 hour withdrawn mice (t(166) = -4.04, p = 0.004; n=9 each), MK-801 pretreated
control mice (t(166) = -4.48, p < 0.004), or 24 hour withdrawn ethanol mice (t(166) = 6.30, p <
0.004; Fig. 2C).
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Figure 2-2: Decreased sensitivity of VTA GABA neurons to muscimol 24 hrs after a single injection
of ethanol. (A) The ratemeter shows the firing rate of a VTA GABA neuron (traces in a, b recorded
at times indicated on graph) recorded in a brain slice from a mouse injected with saline once, 24
hours before recording. This representative neuron had a baseline firing rate of approximately 9.3
Hz. Muscimol (0.01-10.0 µM) inhibited the firing rate of this VTA GABA neuron. All insets are
representative 5 sec traces of GABA neuron spike activity recorded before (inset a) and after (inset
b) 0.1 µM muscimol. (B) The ratemeter shows the firing rate of a GABA neuron, which had a
baseline firing rate of approximately 9.6 Hz. Insets a,b show representative 5 sec traces before and
after application of muscimol in a mouse that was treated with 4.0 g/kg ethanol once, 24 hr before
recording. This mouse was resistant to muscimol’s inhibitory effects up to 1.0 µM. (C) Muscimol
significantly inhibited the firing rate of VTA GABA neurons in saline-injected animals. Muscimol’s
inhibitory effect was significantly reduced 24 hr after a single injection of ethanol, but sensitivity
was restored by administration of MK-801. Sensitivity to muscimol was restored in mice tested 7
days post ethanol injection. (D) Dopamine neurons were equally sensitive to muscimol 24 hr after an
ethanol injection in ethanol-exposed vs air-exposed controls. Asterisks *,** represent significance
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levels p<0.05 and p<0.01 between ethanol and saline groups.

Firing rate was also recorded in putative VTA DA neurons (GAD-67 GFP-negative cells)
24 hours after acute saline or ethanol administration. Muscimol suppressed DA neuron firing rate
in a dose dependent manner (F(4, 28) = 18.19, p = 0.0003; Fig. 2D). A single in vivo ethanol
exposure did not affect DA neuron firing rate (F(1, 9) = 1.41, p = 0.2655). There was no main
effect of withdrawal from a single in vivo exposure to ethanol on sensitivity to muscimol
suppression of DA neuron firing rate (F(3, 28) = 1.52, p = 0.2491).
Muscimol inhibition of VTA neuron firing rate after chronic ethanol
We have reported previously that VTA GABA neurons recorded in freely-behaving rats
evince hyperexcitability and tolerance to acute ethanol following 2 weeks of twice-daily
injections of ethanol (Gallegos et al., 1999). The hyperexcitability of VTA GABA neurons was
optimal 16-24 hrs after withdrawal from the last injection. We used similar methods for
establishing alcohol dependence in GAD-67 GFP mice. Similar to what we reported in rats, we
observed that most ethanol-injected mice exhibited more agitation, less grooming, rigid tail and
piloerection than the saline-injected mice 24 hours after 2 weeks of twice-daily injections of 3.0
g/kg ethanol. Unlike what we found previously in rats in vivo, there was no difference in baseline
VTA GABA neuron firing rate in the slice preparation ex vivo in ethanol-treated mice compared
to saline-treated mice (F(1,12)=0.1, p=0.76; Ethanol = 8.8 ± 1.6 Hz vs Saline = 7.9 ± 0.9 Hz; n=8,
5). Muscimol depressed VTA GABA firing rate in a dose-dependent manner (F(4, 37) = 65.66, p <
0.0001; Fig. 3). Chronic ethanol injections significantly affected the response of VTA GABA
neurons to muscimol (F(4,37) = 3.82, p = 0.0466) recorded 24 hrs after the last ethanol injection. A
priori hypothesis testing with Bonferroni correction revealed that VTA GABA neuron firing rate
differed significantly between chronic saline vs ethanol injected mice at 0.1 μM muscimol in
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Figure 2-3: Decreased sensitivity of VTA GABA neurons to muscimol after chronic ethanol
injections. (A) The ratemeter shows the firing rate of a VTA GABA neuron (traces in a,b
recorded at times indicated on graph) recorded in a brain slice from a mouse injected with
saline twice-daily for 14 days. This representative neuron had a baseline firing rate of
approximately 7 Hz. Muscimol markedly inhibited the firing rate of this VTA GABA neuron, with
suppression of activity at the 1.0 µM concentration. All insets are representative 5 sec traces of
GABA neuron spike activity recorded before (inset a) and after (inset b) 0.1 µM muscimol. (B)
The ratemeter shows the firing rate of a GABA neuron in a mouse that was treated with 3.0 g/kg
ethanol twice daily for 14 days. The baseline firing rate was approximately 12 Hz. This mouse
was resistant to muscimol’s inhibitory effects until it was inhibited by 1.0 µM muscimol. (C)
Muscimol inhibited the firing rate of VTA GABA neurons in chronic saline-treated animals,
which was significantly reduced in chronic ethanol-treated mice. Asterisks *** represent
significance levels p<0.001.
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chronic ethanol-treated mice (Fig. 3B,C; n=7), evincing relative resistance to muscimol
inhibition of VTA GABA neuron firing rate (F(1,48) = 18.97, p = 0.0004; Fig. 3A,C; n=5).
The effects of alcohol dependence on the sensitivity of VTA neurons to muscimol was
also evaluated with CIE vapor exposure (200 mg% for 16 hours/day) and drink-in-the-dark
(DID) ethanol consumption in GAD-67 GFP mice. Mice exposed to ethanol vapors increase their
consumption of alcohol when dependent (Dhaher et al., 2008; Lopez & Becker, 2005). To
validate the utility of our modified vapor chamber system in producing alcohol dependence with
CIE exposure in GAD-67 GFP mice, we calibrated three feedback flowmeter settings (1, 3, and 5
L/min) in a 3 L alcohol pressurized flask with breathalyzer values and blood alcohol levels
(BALs; Sigma Enzymatic method). We obtained breathalyzer values of 52.1 ± 4.2, 130.2 ± 4.8
and 225.6 ± 4.1 mg% (n=6) ethanol and BALs of 46.1 ± 3.7, 119.7 ± 2.9, and 234.9 ± 5.5 mg%
(n=6) ethanol at feedback flowmeter flask settings 1, 3, and 5 L/min, respectively. Based on
these calibrations, a separate cohort of mice was exposed to feedback flowmeter settings
corresponding to 200 mg% breathalyzer values for 16 hours (1000-0200 hours)/day. We
evaluated ethanol consumption in the DID procedure following three weeks of continuous CIE
or air in order to avoid any alcohol exposure in the air-exposed mice. Ethanol vapor-exposed
GAD-67 GFP mice consumed significantly more ethanol than air-exposed mice 24 hr after
withdrawal from three weeks of CIE (F(1,11)=6.9, p=0.02; n=6,8), as well as 9 days after
withdrawal from CIE (F(1,5)=5.94, p=0.02; n=3 each; Fig. 4). In addition, similar to chronic
ethanol injections, we observed that most ethanol-exposed mice exhibited more agitation, less
grooming, rigid tail and piloerection than the saline-injected mice 24 hours after 3 weeks of
ethanol vapor exposure. Thus, three weeks of CIE in our vapor chambers at the 200 mg%
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Figure 2-4: Drink-in-the-dark model of alcohol dependence. In CD-1 GAD-67 GFP mice
exposed to three continuous weeks of CIE vapor (n=3) or air (n=6), ethanol consumption in the
DID test was significantly increased in mice receiving ethanol vapors vs air-exposed mice.
Dependent mice displayed increased drinking 24 hours after withdrawal from CIE vapor, and
again on day 9 after last CIE vapor exposure. On day 9, mice were in 72 hour withdrawal
following the last drinking test performed. Asterisks * mark statistical significance (p<0.05)
between air and CIE vapor groups.
breathalyzer level was used to evaluate the sensitivity of VTA neurons to muscimol in separate
cohorts.
Firing rate was evaluated in VTA neurons 24 hours after three weeks of CIE to alcohol
vapor vs air controls. Similar to chronic ethanol injections, there was no difference in baseline
VTA GABA neuron firing rate in the slice preparation ex vivo in CIE vapor-exposed mice
compared to air-exposed mice (F(1,44)=0.02, p=0.89; Ethanol = 9.6 ± 1.1 Hz vs Air = 9.4 ± 1.0 Hz
n=26, 19). Muscimol depressed VTA GABA neuron firing rate in a dose-dependent manner
(F(4,137) = 27.03, p < 0.0001). Treatment condition altered the response of VTA GABA neurons
to muscimol (F(8, 137) = 4.71, p = 0.0014). A priori hypothesis testing with Bonferroni correction
revealed that VTA GABA neuron firing rate was higher in chronic ethanol animals (Fig. 5B,C)
compared to chronic air animals (Fig. 5A,C) when the slices were perfused with 0.1 μM
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Figure 2-5: Decreased sensitivity of VTA GABA, but not DA neurons, to muscimol after chronic
intermittent ethanol vapor exposure. (A) The ratemeter shows the firing rate of a VTA GABA neuron
(traces a, b recorded at times indicated on graph) recorded in a brain slice from a mouse exposed to
air for 3 weeks. This representative VTA GABA neuron was characterized by irregular activity but
with a baseline firing rate of approximately 7 Hz. The firing rate of this neuron was inhibited by 0.01
µM and suppressed by 0.1 µM muscimol. All insets are representative 5 sec traces of GABA neuron
spike activity recorded before (inset a) and after (inset b) 0.1 µM muscimol. (B) The ratemeter shows
the firing rate of a GABA neuron in a mouse that was exposed to CIE vapor for 3 weeks. The
baseline firing rate was approximately 5 Hz. This VTA GABA neuron was more resistant to
muscimol’s inhibitory effects up to 1.0 µM than its air-exposed control. In fact, the firing rate of this
neuron was mildly enhanced by muscimol at the 0.1 and 1.0 µM concentrations. (C) Muscimol
significantly inhibited the firing rate of VTA GABA neurons in animals exposed to air for three
weeks, which was significantly reduced in mice exposed to CIE vapors for 3 weeks. In addition,
VTA GABA neuron firing rate was resistant to muscimol inhibition after 7 days of withdrawal. (D)
Dopamine neurons were equally sensitive to muscimol in ethanol vapor-exposed mice vs air-exposed
controls. Asterisks *,** represent significance levels p<0.05 and p<0.01, respectively between
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ethanol and air groups.

muscimol (F(1, 202) = 9.93, p = 0.019; n=15, 13) and 1.0 μM muscimol (F(1, 202) = 9.92, p = 0.019;
n=19, 14). Additionally, VTA GABA neurons in ethanol-dependent mice after 7 days of
withdrawal discharged at a higher rate than in chronic air mice during perfusion with 1.0 μM
muscimol (F(1, 202) = 26.27, p < 0.001; n=15, 7).
Firing rate was also evaluated in VTA DA neurons 24 hours after CIE vapor exposure vs
air exposure. Dopamine neuron firing rate was unaffected by chronic ethanol exposure (F(1, 21) =
0.15, p = 0.7003). Muscimol decreased DA neuron firing rate in a dose dependent manner (F(4, 56)
= 34.63, p < 0.0001). Chronic ethanol exposure did not affect muscimol inhibition of DA neuron
firing rate (F(4, 56) = 0.56, p = 0.4854; Fig. 5D; n=14, 9).
Discussion
The overall aim of this study was to investigate the electrophysiological components of
the mechanism underlying the hyperexcitability of VTA GABA neurons following withdrawal
from chronic ethanol. Mainly, we have reported previously that VTA GABA neuron firing rate
often exceeds 100 Hz for 4-8 hrs during withdrawal from chronic ethanol in rats (Gallegos et al.,
1999). This is 4-5X the baseline level of VTA GABA neuron firing rate in naïve rats. In addition,
tolerance accrues to ethanol inhibition of VTA GABA neurons firing rate following 11 days of
chronic ethanol exposure. The focus of this study was to determine the role of GABA(A)Rs in
VTA GABA neuron hyperexcitability produced by acute and chronic ethanol exposure in GAD67 GFP mice, similar to what we have described with opiate dependence (Ting et al., 2013;
Vargas-Perez et al., 2014). VTA GABA neurons are resistant to the GABA(A)R agonist
muscimol following withdrawal from exposure to acute and chronic ethanol, which was not
exhibited in putative VTA DA neurons.
Putative DA neurons in the VTA were not as sensitive to muscimol as VTA GABA
neurons. Muscimol binds to the orthosteric site (i.e. where GABA binds) on the α1 subunit of the
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GABA(A)R. A possible explanation for the decreased sensitivity is that the α1 subunit is
selectively expressed in GABA neurons (Fritschy & Mohler, 1995), but not in DA neurons, in
the VTA (Okada et al., 2004; Tan et al., 2010), and has been implicated in addiction to some
benzodiazepines (Tan et al., 2010). Interestingly, consistent with what has been reported by us
and others (Tan et al., 2010), VTA GABA neurons exhibit much more spontaneous and spikerelated GABA inhibitory input than DA neurons. This phenomenon occurs despite the fact that
GABA neurons have faster firing rates than DA neurons both in vivo and in vitro, which is
operational even with pronounced afferent GABAergic drive. The effects of acute and chronic
ethanol on muscimol effects on putative DA neurons were studied along with GABA neurons.
There are ambiguities associated with their identification in GAD-67 GFP mice, as 5% of the
neurons in the VTA are neither GABA nor DA neurons (Margolis et al., 2012), and some GABA
neurons express GAD-65 (Merrill et al., 2015). Thus, while VTA GABA neurons in GAD-67
GFP mice can be unequivocally identified as GAD-67+ neurons, caution must be taken in the
identification of DA neurons in this study. However, since DA neurons represent 65% of and
GABA neurons 30% of VTA neurons (Margolis et al., 2012), it is highly likely that the GFPnegative neurons were DA neurons.
We show that VTA GABA neurons are less sensitive to the inhibitory effects of
muscimol 24 hours after a single in vivo injection. We were originally surprised by this finding,
because we had hypothesized that chronic ethanol exposure would be required to shift the
sensitivity of VTA GABA neurons to muscimol, as we have demonstrated with opiate
dependence. However, this short-term plasticity was blocked by prior administration of the
NMDAR antagonist MK-801 (0.5 mg/kg), suggesting that NMDAR activation is required for
acute ethanol’s effect on VTA GABA neuron muscimol sensitivity. Because the mechanism is
GLU-dependent, at least with acute ethanol exposure, there must be some connection between
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NMDAR activation and the altered function of GABA(A)Rs on VTA GABA neurons. In support
of this, GLU plasticity on VTA DA neurons has been shown to be induced by GABA(A)R
agonists (Vashchinkina et al., 2014; Vashchinkina et al., 2012). Future studies could address
interactions between GLU and GABA plasticity, or a link between acute NMDAR activation and
an increase in intracellular chloride concentration, which would shift the reversal potential of the
GABA(A)R. Alternatively, blocking NMDARs may result in some upstream hindrance to
learning the novel rewarding stimulus with an end result of decreased plasticity in the VTA due
to ethanol. Some have reported a link between BDNF signaling and NMDA receptor activation
with alcohol and amphetamine exposure (Fuller et al., 2015; Kolb et al., 2005). We remain
interested in BDNF as an intermediate signaling molecule in the establishment of alcohol
dependence, as we have displayed its involvement with opiate dependence (Vargas-Perez, Kee,
et al., 2009). Future experiments could look at NMDA activation or BDNF signaling during the
chronic exposure to ethanol.
An increase in GABA release onto VTA DA neurons in brain slices 24 hr after a single in
vivo exposure to ethanol (2 g/kg) has been reported in C57BL/6 and DBA/2 mice (Melis et al.,
2002; Wanat et al., 2009), suggesting some plasticity in VTA GABA neuron inhibition of VTA
DA neurons that is mediated by NMDARs. Regardless, this state appears to be temporary, as we
show here that the sensitivity of VTA GABA neurons to muscimol is restored 7 days after a
single exposure to ethanol. Most importantly, DA neuron sensitivity to muscimol was unaffected
by a single exposure to ethanol. While there are two studies demonstrating down-regulation of
the α1 subunit of the GABA(A)R in the VTA with 12 weeks of chronic ethanol (Charlton et al.,
1997; Ortiz et al., 1995), we know of only one study identifying the specific GABA(A)R
subunits expressed in VTA GABA neurons (Tan et al., 2010). A reduction in the levels of the
GABA(A)R α1 subunit has been documented in the VTA with chronic ethanol (Charlton et al.,
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1997; Ortiz et al., 1995; Papadeas et al., 2001). The possibility exists that this reduction is the
underlying mechanism for the decreased sensitivity of VTA GABA neurons to muscimol and the
lack of sensitivity of VTA DA neurons in mice exposed to chronic ethanol.
Two models of chronic exposure to ethanol were used in this study: twice daily injections
of ethanol and CIE in vapor chambers. As mentioned above, we have shown in previous studies
that VTA GABA neurons recorded in freely-behaving rats evince hyperexcitability and tolerance
to acute ethanol following 2 weeks of twice-daily injections of ethanol (Gallegos et al., 1999).
The hyperexcitability of VTA GABA neurons was optimal 24 hrs after withdrawal from the last
injection. Here we show that VTA GABA neurons recorded during withdrawal from twice-daily
injections of ethanol resulted in lowered sensitivity to muscimol compared to saline-injected
control mice. In effect, lowered sensitivity of GABA(A)Rs on VTA GABA neurons might
explain why VTA GABA neurons become hyperexcitable during withdrawal, as they could be
experiencing less inhibition from other local circuit GABA neurons or projection GABA neurons
from the NAc, ventral pallidum, etc. While chronic injection studies are supportive, it is difficult
to determine dependence in rats and mice. The CIE vapor chamber approach enables
determinations of dependence, mainly increased alcohol drinking, and eliminates the risk of
infection from repeated injections. We show the validity of our alcohol vapor chamber system
for establishing alcohol dependence using increased alcohol consumption. Similar results have
been shown using DID as a measure of alcohol dependence in other labs (Dhaher et al., 2008;
Lopez & Becker, 2005). We compared drinking between ethanol-exposed and naïve air-exposed
mice in the DID procedure after withdrawal from 3 weeks of 16 hrs ON, 8 hrs OFF CIE and
found that ethanol consumption increased significantly at 24 hours and 9 days after withdrawal.
After chronic exposure to ethanol vapors, VTA GABA neuron firing rate is also resistant to the
inhibitory effects of muscimol, but importantly, this resistance persists after 7 days of withdrawal
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from chronic ethanol but not acute ethanol exposure. None of these effects were seen in putative
VTA DA neurons.
The fact that alterations in muscimol sensitivity are seen only in VTA GABA neurons
and not VTA DA neurons strengthens the claim that alcohol’s effects on DA in the brain are
mediated through VTA GABA neurons. Rather than DA elevation due to alcohol being caused
by a direct action on DA neurons, ethanol could disinhibit DA neurons through acting on VTA
GABA neurons. We have previously shown that VTA GABA neurons are hyperexcitable during
withdrawal from chronic alcohol (Gallegos et al., 1999), which might explain the
downregulation of DA neural activity and DA release that is characteristic of alcohol
dependence. This decrease of DA activity during withdrawal could contribute to the increased
hedonic drive to seek alcohol in order to alleviate the negative consequences of withdrawal.
However, it is important to note that VTA GABA neuron baseline firing rate measured in the ex
vivo slice did not differ between ethanol-exposed and control groups. This finding runs counter
to our hypothesis. Thus, we cannot rule out changes in circuit responses to explain increased
muscimol resistance in ethanol exposed mice. The discrepancy between in vivo and ex vivo
recordings may be due to the loss of GLUergic and GABAergic inputs due to slicing. Indeed,
GLU transmission may be a critical player, as our MK-801 experiments would suggest: mainly,
that MK-801 reverses ethanol-induced muscimol resistance 24 hr after a single intoxicating dose
of ethanol. Regardless, as hypothesized, changes in muscimol sensitivity would still suggest that
there could be a decrease in number of GABA(A)Rs, the affinity of GABA(A)Rs for muscimol,
a change in subunit composition of the GABA(A)R (e.g. α1 subunit), enhanced GABA(A)R
desensitization, or a shift in function of the GABA(A)R, as we have reported in a series of papers
with opiate dependence (Laviolette et al., 2004; Ting et al., 2013; Vargas-Perez et al., 2014;
Vargas-Perez, Kee, et al., 2009). Future studies with perforated patch recordings in dissociated
30

neurons from alcohol-dependent mice and/or chloride imaging will address this issue,
particularly with regard to the chloride gradient and the reversal potential of GABA(A)Rs. We
are currently developing a procedure to perform perforated-patch clamp recordings in mature
animals to address this question.
In conclusion, this study examined the inhibitory effects of the GABA(A)R agonist
muscimol on VTA neurons following alcohol exposure. VTA GABA neurons display resistance
to muscimol’s inhibitory effects following both acute and chronic exposure to ethanol, that
persists following chronic exposure, which has implications for the state of the GABA(A)Rs on
VTA GABA neurons along the continuum of alcohol dependence. The changes described in this
study contribute to altered function of VTA neurons during withdrawal from alcohol that may
contribute to the motivation for alcohol-seeking behaviors in dependent individuals.
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Abstract
Brain-derived neurotrophic factor (BDNF) is implicated in varied physiological processes. Its
main receptor in the central nervous system is tyrosine receptor kinase B (TrkB), and the main
ligand for TrkB in the central nervous system is BDNF. It has been shown previously that
activating TrkB can cause a downregulation of the chloride-exporting potassium chloride
cotransporter 2 (KCC2), presumably resulting in a decreased chloride gradient. We have shown
previously that opioid dependence produces a functional switch in GABA(A) receptors on
GABA neurons in the ventral tegmental area (VTA) during opioid dependence that is mediated
by BDNF and TrkB. It is hypothesized that this switch, caused by an increase in BDNF levels,
elicits hyperexcitable GABA neurons in the VTA due to a reduced efficacy of inhibitory
currents. Here we investigate this mechanism of adaptation in the context of chronic alcohol
exposure. We demonstrate that BDNF levels are elevated in the VTA and the nucleus
accumbens (NAc) during withdrawal from chronic ethanol (EtOH) exposure. We also observe
that blocking TrkB activity decreases EtOH seeking behavior in non-dependent animals.
Further, we investigate the expression patterns of KCC2 in connection with chronic EtOH
administration. Additional work is underway to validate this mechanism and further elucidate its
putative role in alcohol dependence.
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Introduction
Alcohol addiction has caused immeasurable grief to individuals, families, and
communities. Furthermore, it has staggering financial and health consequences. Nearly 17
million Americans have an alcohol use disorder (AUD), and approximately 1.3 million adults
received treatment for an AUD (Health, 2016; SAMHSA, 2016). The estimated economic costs
of AUD to the US in 2015 was $249 billion, and almost three-quarters of the total cost was
related to binge drinking (Sacks et al., 2015; SAMHSA, 2016). In 2000 there were roughly
85,000 alcohol-related deaths in the U.S. making alcohol consumption the number three
preventable cause of death (Mokdad et al., 2004). The current therapies for alcoholism have a
low success rate, and more effective treatments are in significant need. At present, there is much
left to understand about the molecular actions of alcohol and the neural mechanisms that lead to
alcohol addiction as well as how interventions might be devised to mitigate it.

Figure 3-1: The circuit of interest: (top) DA neurons originate in the VTA and project to the
NAc, (bottom) Illustration of some of the synapses of interest. VTA GABA neurons receive
inhibitory input from other brain regions.
A commonly accepted theory of addiction is that it has its genesis in alterations to neural
dopamine (DA) transmission. The DA circuit of greatest interest is the mesocorticolimbic or
mesolimbic DA system, which is critical for reward and reinforcement circuitry. This system
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begins in the ventral tegmental area (VTA) in the midbrain and projects to areas of the cortex
and limbic system, including the nucleus accumbens (NAc) (see Fig. 1). The connection from
the VTA to NAc is highly implicated in reward and addiction. While DA release in the NAc is
not necessarily a direct measure of reward, it is critical to reinforcement of behaviors.
There are three types of neurons in the VTA: DAergic, inhibitory ᵞ-aminobutyric acid
(GABA)ergic, and excitatory glutamatergic neurons, which comprise 65%, 30% and 5% of VTA
neurons, respectively (Dobi et al., 2010). Under normal circumstances, GABA connections in
the VTA regulate DA release in response to normal synaptic GABA release by allowing inward
flux of chloride (Cl-) ions following activation of GABAARs. We have shown previously that
these GABA neurons are particularly sensitive to EtOH (EtOH) and change their activity levels
after extended exposure, becoming hyperexcitable during withdrawal from chronic EtOH
exposure, exhibiting firing rates that often exceed 100 Hz for hours (Gallegos et al., 1999). It is
thought that some of this change is mediated by brain-derived neurotrophic factor (BDNF)
(Vargas-Perez et al., 2014; Vargas-Perez, Ting, et al., 2009). VTA GABA neurons also receive
inhibitory input from other brain regions, which is the main synapse of focus in this study.
Brain-Derived Neurotrophic Factor
Brain-derived neurotrophic factor (BDNF) is a peptide in the neurotrophin family, a
group of four known compounds with similar molecular weight and structure (Hallbook, 1999).
The first neurotrophin, nerve growth factor (NGF), was discovered in the 1950’s due to its ability
to facilitate neuron survival (Levi-Montalcini & Hamburger, 1951). Roughly 30 years later the
second neurotrophin, BDNF, was isolated from pig brain tissue (Barde et al., 1982). Since then,
considerable evidence has mounted that BDNF, like NGF, also imbues cells with enhanced
survival in a variety of areas in the nervous system [reviewed in (Huang & Reichardt, 2001)].
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BDNF finds widespread expression in discrete areas of the nervous system, including structures
such as the hippocampus and various thalamic and brainstem nuclei (Conner et al., 1997).
Importantly, it plays a role in proper memory function and neural plasticity, both of which are
factors in addiction (Bekinschtein, Cammarota, Izquierdo, et al., 2008; Bekinschtein,
Cammarota, Katche, et al., 2008; Yamada & Nabeshima, 2003). Additionally, it has been known
to play a role in neural development and in neurogenesis (Huang & Reichardt, 2001; Zigova et
al., 1998). There is also some evidence that BDNF could be linked to a variety of diseases,
including but not limited to depression and Alzheimer’s disease (Dwivedi, 2013; Zhang et al.,
2012). There are two main receptors for BDNF: the tyrosine receptor kinase B (TrkB) and the
p75 receptor (Patapoutian & Reichardt, 2001). The latter will not be discussed here, but could
also be worth investigating with a similar approach to the one described here. TrkB is the main
receptor for BDNF and BDNF is the main ligand for TrkB, although a second ligand, NT-4, does
exist [reviewed in (Hempstead, 2015; Huang & Reichardt, 2001)]. This receptor is gaining
interest as a therapeutic target for conditions such as Alzheimer’s disease, obesity, and
depression, as mentioned above in connection with its primary ligand. It is worth noting,
however, that using TrkB as a therapeutic target must be done with care, as it has been observed
that mice that overexpress BDNF exhibit deficits in memory and can later experience
epileptiform activity (Cunha et al., 2009; Isgor et al., 2015; Scharfman, 1997).
Potassium-Chloride Cotransporter 2 (KCC2)
One of the downstream effects of activating TrkB can be the downregulation of the
potassium chloride cotransporter 2 (KCC2), as has been observed in the hippocampus (Rivera et
al., 2002). KCC2 is a neuron-specific membrane protein expressed only in the central nervous
system (Sivakumaran et al., 2015; Wu et al., 2016). One of its main roles is that of removing Clions from the intracellular space, thus helping to maintain a normal Cl- gradient (Gagnon et al.,
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2013; Payne, 1997; Sivakumaran et al., 2015). It is closely related to Na+ K+ Cl- cotransporters 1
and 2 (NKCC1 and NKCC2). These are not neuron specific but can have the effect of importing
Cl- into the cell (Arroyo et al., 2013). Both groups of transporters affect the Cl- gradient, which
is critical to the proper functioning of inhibitory synapses, and dysregulating it could cause
certain cells to become hyperexcitable. This is evidenced by the selective inhibition of KCC2,
which yields epileptiform activity (Sivakumaran et al., 2015). It is also worth noting that the
complete removal of the KCC2 gene causes death at birth due to hypoxia (Hubner et al., 2001).
Furthermore, it is thought that BDNF signaling from microglia may be a cause for neuropathic
pain; a condition of hypersensitive pain pathways (Coull et al., 2005). For this reason KCC2 has
recently been evaluated as a pharmacological target for CNS disorders such as neuropathic pain
and morphine-induced hyperalgesia (Gagnon et al., 2013). We have shown previously that intraVTA administration of furosemide, a non-selective KCC2 inhibitor, produces effects similar to
those found in chronic opiate dependence (Ting et al., 2013).
Combined Model
To combine these mechanisms (see Fig. 2), our model suggests that BDNF acts on TrkB
to down-regulate KCC2 in the VTA. Because KCC2 normally removes Cl- from the intracellular
space, its down-regulation leaves an excess of Cl- inside the cell. This results in a shift in the
excitability of the cell. This hyperexcitability is manifest in what is known as the Cl- reversal
potential, or rather, the membrane potential at which the normal direction of Cl- ion flux
reverses. This shift occurs in GABAA receptors in response to opiates, which we call GABA
switching (Vargas-Perez, Ting, et al., 2009).
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We hypothesize that GABA switching caused by activation of this BDNF/TrkB/KCC2
pathway is playing an important role in the development of EtOH dependence, as it is involved
in opiate dependence. In order to test this hypothesis, we have transected this pathway at two

Figure 3-2: A representation of the current working model for alcohol dependence. A) In an
alcohol-naïve state (Cl-) ions flow inward through GABAA channels in response to GABA
release, causing an inhibitory hyperpolarization of the cell and KCC2 then removes excess Clfrom the intracellular space. B) In a dependent state, BDNF activates TrkB, which
downregulates KCC2, yielding higher residual Cl- inside the cell and allowing Cl- to flow
outward through the GABAA channel and cause an excitatory depolarization of the cell.
different points: TrkB and KCC2. We activated and blocked TrkB using an agonist and
antagonist and only activated KCC2 due to the extreme consequences of selective inhibition of
KCC2. We established dependence through a chronic intermittent EtOH (CIE) methodology or
through chronic injections.
Methods
Animals
All animals used in this study were treated in compliance with the Institutional Animal
Care and Use Committee (IACUC) at Brigham Young University (BYU). Male mice older than
postnatal day 28 were group housed except as experimentally required during drinking
paradigms and were given ad libitum access to standard mouse chow and water. Animal housing
was maintained on an inverted light cycle with lights turning off at 10:00 and turning on at 22:00
each day. Any activities conducted during the animals’ dark cycle were performed using red
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light to minimize interruption of circadian rhythms (Barbini et al., 1996; Roedel et al., 2006; Van
den Hoofdakker & Beersma, 1988). Strains used include a C57BL/6J wild type strain and a
GAD67 GFP+ strain on a CD-1 background.
Drug Administration
Chronic injections of EtOH or saline as well as acute injections of ANA-12 (Tocris and
Cayman Chemical), 7,8-dihydroxyflavone (Sigma), and vehicle were accomplished via
intraperitoneal injection using a sterile 27-gauge needle. Chronic injections of EtOH and saline
were done twice daily for a minimum of 12 days. For drinking studies, acute injections were
administered 3 hr prior to the commencement of the drinking session to ensure that the 4 hr
timepoint was during the session (Cazorla et al., 2011). For immunohistochemistry (IHC)
studies, acute injections were given 4 hr prior to cardiac perfusion.
ELISA
Measures of brain-derived neurotrophic factor (BDNF) and its precursor, proBDNF, were
obtained using an enzyme-linked immunosorbent assay (ELISA) kit (Biosensis Cat. No. BEK2211-1P & BEK-2217-1P respectively). The standard Biosensis sample preparation for brain
tissue extracts using RIPA buffer was used. In short, tissue samples were extracted and snap
frozen in liquid nitrogen then stored at -70°C until time of use. They were then homogenized via
sonication in ice cold RIPA buffer containing 50 mM Tris-HCl, 150 mM NaCl, 1.0% Triton X100, and 0.5% sodium deoxycholate with a pH between 7.5-8.0. Samples were kept on ice for
30 min, and homogenization and ice-cold incubation were repeated. The homogenate was
centrifuged at 10,000-20,000 x g at a temperature of 4 °C for 30 min and the supernatant fluid
was transferred into new centrifuge tubes and stored at -70 °C. The samples were then
centrifuged under the same conditions prior to being used in the ELISA.
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Alcohol Consumption
Alcohol consumption was measured using a drinking in the dark (DID) model of binge
drinking as previously described or a similar two-bottle choice paradigm (Anderson et al., 2016).
In the DID paradigm, C57 mice were single housed during the duration of the experiment to
ensure that consumption rates could be individually measured for each mouse. During each
drinking session, the water bottle was removed and replaced by a bottle containing 20% EtOH,
diluted from a 190 proof stock (Decon Laboratories, Inc.). At the conclusion of the session, the
EtOH bottle was removed and the water bottle was returned to the cage. The EtOH bottle was
weighed before and after each session, and three control bottles were placed in empty cages to
control for evaporation, drips during the session, and loss during the inversion of the bottle.
Ethanol solutions were made fresh each day. Drinking sessions were scheduled 4 days per week
with the first three sessions lasting 2 hr and the final session lasting 4 hrs. The drinking sessions
began at three hours into the dark cycle, for optimal activity. Drinking sessions were
administered for two weeks prior to chronic EtOH exposure and two weeks following chronic
EtOH exposure. In the two-bottle choice paradigm, the mice were placed in separate cages at the
beginning of the session and presented with two bottles: one containing water and one containing
20% EtOH. Consumption was measured by volumetric graduations, and testing was performed
5 days per week, 2 hr per session. They were returned to their home cages after the session. All
other details of the procedure are the same as in the DID paradigm.
Chronic Intermittent EtOH
To produce dependence, mice were exposed to EtOH vapors using a chronic intermittent
EtOH (CIE) paradigm (Becker & Lopez, 2004; Griffin et al., 2009). In short, air was bubbled
through an EtOH bath and then supplied to half of the cages for 16 hours per day. The EtOH
used was 200 proof to prevent accumulation of water in the flask (Decon Laboratories, Inc.).
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This exposure began at 10:00 each morning and concluded at 02:00 the following morning.
Mice received EtOH in this manner for four consecutive days each week and were then given air
with no EtOH for the following 3 days. The schedule was controlled automatically by a timer
and electrically operated solenoid valve. This schedule was kept for 6 total weeks of exposure,
after which DID was repeated. The other half of the cages received clean air during the entire
CIE schedule.
Immunohistochemistry
Brains used in IHC studies were preserved using cardiac perfusion of phosphate buffered
saline (PBS) and then 4% paraformaldehyde (Alfa Aesar). Brains were then extracted and stored
overnight in 4% paraformaldehyde (PFA). The brain was then moved to a 10% sucrose solution
and incubated at 4 °C until it dropped to the bottom of the vial. It was then moved to a 20%
sucrose solution and then a 30% sucrose solution, incubating at 4 °C each time until the brain
sank to the bottom of the vial. The brains were then fixed to a microtome (American Optical
Company, model 860) and frozen using dry ice. Slices containing the VTA or NAc were
prepared at a thickness of 40 µm and stored in cryoprotectant. Slices were incubated in primary
antibodies for KCC2 (Rabbit anti-KCC2 polyclonal antibody, ThermoFisher Cat No. PA578544, 1:500 dilution) and FOX3/NeuN (Mouse anti-FOX3 monoclonal antibody, EnCor
Biotechnology Cat. No. MCA-1B7, 1:1000 dilution) as well as secondary antibodies (Donkey
Anti-Rabbit IgG H&L AlexaFluor 647, 1:1000 dilution, and Goat Anti-Mouse IgG H&L
AlexaFluor 405, 1:1000 dilution, Abcam Cat. Nos. ab150075 & ab175660 respectively).
Primary antibodies incubated for 18 hrs at 4 °C and secondary antibodies incubated for 2 hrs at
room temperature, all while being gently agitated using an orbitron rotator (Boekel Scientific).
Next, slices were mounted to microscope slides using Vectashield (Vector Laboratories). A
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confocal microscope was used to generate a Z stack for each image, and image analysis was
accomplished using a custom workflow (available upon request).
RESULTS
BDNF and Pro-BDNF Expression in EtOH Withdrawal
Prior to investigating any effects of EtOH on TrkB or KCC2, it was imperative to
understand whether BDNF expression is altered in chronic alcohol exposure. Since an increase
in BDNF expression is the beginning of the mechanism proposed in this model, this was a
critical point to validate prior to proceeding. We conducted an ELISA to evaluate the expression
of mature BDNF as well as its precursor pro-BDNF in mice that had been exposed to at least
three weeks of CIE or clean air in the vapor chambers. This was done at 24 hours of withdrawal
and 7 days of withdrawal to assess how long the effects would last. We also made these same

CHRONIC

Figure 3-3: BDNF expression in the VTA (Left) and NAc (Right) of mice exposed to acute vs.
chronic ethanol, including time points at 1 day of withdrawal and at 7 days of withdrawal. Acute
exposure was administered by injection of saline vs. EtOH and chronic exposure was
administered using the CIE methodology. The air group received no alcohol in the air supply.
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measurements on animals that had received only a single intraperitoneal injection of EtOH or
saline to compare the acute and chronic effects of alcohol on BDNF expression. We found that
there were no acute alterations to mature BDNF or pro-BDNF at 8hr, 16hr, or 24hr of withdrawal
from a single intraperitoneal injection (2.5g/kg) of alcohol. However, mature BDNF was
significantly increased in withdrawal from chronic alcohol exposure (Fig. 3). Twenty four hours
after the last exposure to EtOH, BDNF expression in the VTA and NAc was significantly
increased, which effect persisted at 7 days of withdrawal. In the NAc, this same pattern occurred
but with a much more muted amplitude.
Effects of BDNF on VTA GABA Neuron Firing Rate
With an understanding of the increased expression of BDNF in the VTA in withdrawal
from chronic alcohol exposure, and in light of the fact that VTA GABA neurons are
hyperexcitable under these same circumstances, we desired to know if BDNF was having direct
effects on GABA neurons in the VTA, causing this hyperexcitability (Steffensen et al., 2009).
We measured this using patch clamp electrophysiology in an acute brain slice preparation. We

Figure 3-4: Firing rate of VTA GABA neurons appears not to be impacted by acute superfusion
of BDNF. (Left) Mean firing rate as a % of baseline with acute superfusion of BDNF first and
the TrkB antagonist ANA-12 next. (Right) A representative trace illustrating the pattern of firing
rate as it progresses throughout the experiment.
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found that with acute application of BDNF via superfusion, no change in VTA GABA neuron
activity was significant, although a slight trend toward an increase exists, which then disappears
with the TrkB antagonist ANA-12 (Fig. 4). This was measured on the 5 min and 30 min
timescale.
Alcohol-induced Changes in KCC2 expression
After determining that there were not clear effects of acute BDNF superfusion on VTA
GABA neuron firing rate, we wanted to determine what chronic changes were occurring in the
BDNF pathway in response to the increase in BDNF observed in Fig. 3. To accomplish this, we
evaluated the expression of KCC2 in an alcohol naïve state and in alcohol withdrawal.

Figure 3-5: Fluorescence imaging of brain slices with a transgenic GAD67-GFP marker in the
green channel, a NeuN neuronal stain in the blue channel, and a KCC2 stain in the red channel.
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We measured KCC2 expression using immunohistochemistry (IHC) and fluorescence
microscopy with a transgenic GAD67-GFP marker in the green channel, a NeuN neuronal stain
in the blue channel, and a KCC2 stain in the red channel (Fig. 5). We observed that chronic
alcohol increased the expression of KCC2 in both the NAc and the VTA without any drugs
applied (Fig. 6). When a TrkB agonist (7,8-DHF) was given IP 4hrs prior to fixing the brain, the
effect was maintained, and expression increased further in both the chronic saline and chronic
alcohol conditions. When a TrkB antagonist (ANA-12) was given IP 4hrs prior to sacrificing the
animal, the effect was reversed, and a decrease in KCC2 expression was observed in response to
chronic EtOH exposure. This was an unexpected result and will be discussed in more detail
hereafter.

Figure 3-6: Immunohistochemistry group means in the ventral tegmental area (VTA) and
nucleus accumbens (NAc). Mice were chronically injected with either saline or EtOH and given
an acute injection of ANA-12, 7,8-DHF, or vehicle 4 hours before cardiac perfusion.
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Role of TrkB in EtOH seeking behavior
Prior to measuring EtOH seeking behavior, we wanted to validate that the CIE
methodology we employed caused an increase in drinking, which we use as an indirect measure
of dependence. To accomplish this, we first measured baseline drinking behavior using a twobottle choice paradigm and then administered one week of CIE. We then repeated this cycle
another three times for weeks 3-8, and on the fourth cycle we omitted the CIE in week 9 and
allowed the animals to withdraw then measured drinking for one more week to see if the increase
in drinking persisted after a week of withdrawal. We observed that after the second week of
CIE, there was a significant difference in drinking behavior between the EtOH vapor mice and
the air mice, which continued to amplify through week 8 (Fig. 7). After one week of withdrawal
in week 9, the drinking in the EtOH exposed mice began to reduce slightly but was still
significantly higher than the air exposed mice, suggesting persistent dependence.
With this tool validated, it was critical to ascertain whether this BDNF pathway impacts
EtOH seeking behavior. To assess this, we used a modified drink-in-the-dark (DID) paradigm in
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Figure 3-7: Drinking behavior as measured by two bottle choice, showing an increase in
drinking behavior in the EtOH exposed mice with no increase in the air exposed mice.
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conjunction with CIE. First, we measured baseline drinking behavior before any chronic alcohol
administration. Following a 6-week CIE period, we retested drinking for a week to assess
whether CIE produced an increase in drinking behavior. We then measured drinking for another
week with an acute injection of a TrkB drug or vehicle 3.5 hours prior to each session.
We observed that drinking behavior did increase after CIE for the mice exposed to EtOH,
as expected (Fig. 8). As predicted, the air control mice showed an increase in drinking behavior
when given a TrkB agonist and a decrease in drinking behavior when given a TrkB antagonist.
However, there was no significant difference between the mice that received EtOH during CIE
when either drug was given.
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Figure 3-8: Alcohol consumption in response to CIE and TrkB drugs. (Top left) Alcohol
consumption before and after CIE for both the air-exposed mice and the EtOH-exposed mice.
(Top right) Consumption after CIE with an acute injection of ANA-12 or vehicle. (Bottom)
Consumption after CIE with an acute injection of 7,8-DHF or vehicle.
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Discussion
BDNF Expression
Consistent with our hypothesis, we found that BDNF expression increased in the VTA in
withdrawal from CIE exposure but not following acute EtOH exposure. This effect persisted for
at least 7 days, suggesting that the increase was related to adaptations that occurred as a result of
CIE exposure. This same trend was observed in the NAc but was less pronounced.
It has been shown that BDNF has preservative functions in the brain (Acheson et al.,
1995). Consequently, one might expect it to have protective effects as well. Our data suggest
that BDNF is likely having an adverse effect in this context, contrary to its typical functions.
Since EtOH is a solvent harmful to living tissues (used as a sanitizing agent at high
concentrations), it seems reasonable to postulate that the BDNF secretions we report are
generated in response to perceived damage or dysregulation caused by EtOH and are intended to
be protective but result in deleterious effects. Additionally, we have reported a connection
between BDNF and opiate dependence (Vargas-Perez et al., 2014; Vargas-Perez, Ting, et al.,
2009). So, while the peptide may have positive effects in some cases, there is evidence it can
also be detrimental. At this point, it is unclear whether this increase in BDNF is the result of
microglia or synaptic release. This is worthy of future investigation.
VTA GABA Neuron Activity
Since it is apparent that BDNF is over-expressed in EtOH withdrawal, we wanted to
determine if it was having direct effects on naïve VTA GABA neurons, given their robust
adaptations to chronic EtOH. We found that there were no obvious changes in activity in GABA
neuron activity in naïve mice with the slight exception of a subtle trend toward an increase in
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firing rate, which is reversed by the TrkB antagonist ANA-12. With a larger sample size it could
be verified whether this is a real effect or noise.
Changes in KCC2 Expression During Withdrawal from Chronic EtOH
The KCC2 IHC yielded unexpected results. In the animals that received chronic saline
injections, there were no differences in KCC2 expression in the VTA when a TrkB agonist or
antagonist was given. Consistent with our expectations, we observe a decrease in KCC2
expression in the VTA in withdrawal from CIE exposure and without exposure to any additional
drugs. We hypothesized that ANA-12 would block this effect, but it reduced expression. We
hypothesized that 7,8-DHF would decrease expression, but we observed an increase in
expression compared to our vehicle condition. Interestingly, the TrkB agonist and antagonist
had opposite effects, which gives added credibility to these results, but the expression patterns
shifted in the opposite direction of what we expected. Similar results were noted in the NAc
with the notable exception being that in the chronic saline-injected animals we did see an
increase in KCC2 expression with both the TrkB agonist and antagonist.
These results are difficult to interpret within the theoretical construct of our current
model. However, additional experiments are underway to validate these results.
Role of TrkB Receptors in EtOH Consumption
Prior to using our CIE methodology, it was essential to validate that this procedure
produced evidence of dependence. We measured drinking behavior alternating with CIE every
other week, and we observed that the mice who received EtOH during the CIE weeks increased
their drinking while those that received only clean air during the CIE weeks did not. This
confirms that our CIE apparatus and methodology produces an increase in drinking for mice
exposed to EtOH vapors.
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When we injected ANA-12 after 6 weeks of CIE, we discovered that it reduced drinking
behavior. This was consistent with our hypothesis, but the effect was only observed in the airexposed animals. The EtOH dependent animals were unaffected by the ANA-12 injection. This
could be due to adaptation of TrkB receptors because of repeated withdrawal sessions during the
weeks of CIE. As we noted above, BDNF expression increases substantially in the VTA in
withdrawal from CIE exposure, and during CIE the mice were withdrawn from alcohol every
weekend for three days. It is therefore possible that during this time the increased exposure to
BDNF secretions caused a downregulation of TrkB, which would have reduced the impact of
ANA-12 in our drinking paradigm.
When we injected 7,8-DHF under the same circumstances, the result was the functional
opposite of the ANA-12 injections. We observed an increase in drinking behavior in the airexposed group, but again, we saw no difference in the dependent group. This also supports the
idea that perhaps there is TrkB adaptation occurring in CIE exposure that is blunting the effects
of the TrkB drugs.
Conclusion
In summary, it is apparent that the BDNF/TrkB/KCC2 pathway is involved in EtOH
consumption, but there is yet much to uncover about the specifics of this involvement. The fact
that the TrkB antagonist did not decrease drinking in EtOH-dependent animals (as assessed by
increased drinking) reduces the therapeutic potential of using TrkB as a drug target for AUD.
However, there is still much potential for KCC2 to be used as a drug target, and it seems
probable that blocking KCC2 will result in very few side effects, since activating KCC2 will
reduce intracellular chloride levels, and those levels are already low in healthy individuals.
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Thus, it would represent a use-dependent therapeutic approach. Future work is needed to further
elucidate the potential of KCC2 as a novel target for AUD therapeutics.
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Abstract
Cluster of differentiation 5 (CD5) is expressed in both T and B cells and has been found to
display an altered expression profile following chronic ethanol use and during ethanol (EtOH)
withdrawal. Specifically, the number of CD5+ B cells is reduced during withdrawal while the
number of T cells is increased. Given the apparent sensitivity of these cells to EtOH, and recent
research suggesting that some of EtOH’s effects are accounted for by neuroimmune interactions,
we assessed EtOH drinking behavior and sedation in CD5 knockout (KO) mice. We found that
CD5 KO mice display decreased EtOH consumption compared with wild-type (WT) controls in
a 24-hour access two-bottle choice drinking paradigm. Additionally, CD5 KO mice displayed
considerable resistance to the sedating effects of EtOH. We found no difference in dopamine
release dynamics in the nucleus accumbens nor in the ethanol-induced inhibition of GABA
neurons in the ventral tegmental area, both of which are neuronal substrates implicated in the
rewarding properties of EtOH. These results suggest that CD5 KO mice are less sensitive to
some of the effects of EtOH and that peripheral neuroimmune mechanisms involving CD5 may
be a factor in EtOH consumption and sedation.

53

Introduction
Unlike most drugs of abuse, the mechanisms of action of ethyl alcohol (EtOH) on the
brain remain largely elusive. It has been proposed that interactions between the nervous system
and the immune system could mediate some of the acute effects of EtOH on the brain, and the
evidence base to support this hypothesis continues to grow. Relatedly, it has been observed that
some immune factors are sensitive to chronic EtOH administration (Margoles et al., 2016; Zhang
et al., 2017). One such marker is cluster of differentiation 5 (CD5).
T cells are key players in the adaptive immune response. Sometimes called Ly-1 (or Lyt1) in mice and Leu 1 in humans, CD5 is a 67kDa trans-membrane glycoprotein that is expressed
on T cells and B cells with a higher expression on T cells (Huang et al., 1987; Youinou et al.,
1999). It has been reported that CD5 has numerous effects on the immune system as well as
effects on related systems. It is known to regulate development, intracellular signaling, and
cytokine production (Henderson et al., 2015; Li et al., 2019). Additionally, it has been shown to
be a positive and negative regulator of T cell receptor signaling, a negative regulator of B cell
receptor signaling, and a promoter of mature T cell survival [Reviewed in (Burgueno-Bucio et
al., 2019)]. It has also been found that CD5 can regulate basal NF-κB signaling in T cells
(Matson et al., 2020). Because of its high level of structural conservation between the murine
and human forms, it is sometimes assumed to be of critical importance (Huang et al., 1987).

B

cells that are CD5+ play a crucial role in regulating myelinization of neurons during
development while T cells contribute to synaptogenesis during development (Tanabe &
Yamashita, 2018; Zarif et al., 2018; Ziv et al., 2006). Specifically, T cells encourage the creation
of inhibitory synapses to GABA neurons while discouraging the creation of excitatory synapses
through interferon γ (Brask et al., 2004; Fujita et al., 2017; Kim et al., 2002). Furthermore, it’s
been reported that B cells that are CD5+ produce more interleukin-10 (IL-10) than CD5- B cells
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and it has been observed that the soluble form of CD5 can bind interleukin-6 (IL-6) (AparicioSiegmund et al., 2017; Gary-Gouy et al., 2002). This in conjunction with our recent observations
that IL-10 and other cytokines may be influential in the rewarding and reinforcing properties of
EtOH or other drugs of abuse makes CD5 particularly interesting (data not yet published).
Neurons in the ventral tegmental area (VTA) have been shown to be sensitive to the
effects of EtOH (Steffensen et al., 2009; Stobbs et al., 2004). In particular, GABA neurons are
known to be inhibited by an acute dose of EtOH, at doses of EtOH that are physiologically
relevant to reward, while dopamine (DA) neurons are excited by acute EtOH, albeit at high
levels of EtOH (Brodie et al., 1990; Gessa et al., 1985). These effects are seen both in vivo and in
vitro, albeit with greater sensitivity in vivo. Additionally, in chronic EtOH exposure, VTA
GABA neurons become hyperexcitable during withdrawal from EtOH (Gallegos et al., 1999).
Interferon γ is known to both enhance and inhibit GABAergic tone and is also known to have
increased expression following EtOH consumption, with T cells serving as one of the main
sources for interferon γ in the VTA (Duncan et al., 2016; Filiano et al., 2016; Janach et al., 2020;
Johnson et al., 2015; Laso et al., 1999; Muller et al., 1993; Pascual et al., 2015; Zhu et al., 2011).
The purpose of this study was to evaluate the impact of CD5 expression on EtOH effects
in a mouse model. It was hypothesized that CD5 would play a role in the acute effects of EtOH
and that the brain in a CD5-deficient animal would be found in a hyper-DAergic state. The
results of this study add to the understanding of the acute effects of EtOH on the brain, an area
which is in much need of additional insight and novel substrates to consider for treatment of
AUD.
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Methods
Animal Subjects
This study was conducted using male and female CD5 knockout (CD5 KO) mice on a
C57BL/6J background. As a genetically similar control, male and female C57BL/6J mice were
used. The data from the male and female cohorts were compared for similarity and conjoined if
there were no significant sex differences. All mice were bred, housed, and handled in
compliance with the National Institutes of Health (NIH) Guide for the Care and Use of
Laboratory Animals. Procedures and protocols were approved by the Institutional Animal Care
and Use Committee (IACUC) at Brigham Young University (BYU) in Provo, Utah. Mice were
only used for this study after postnatal day 28. For the drinking paradigm, the mice were not
used until their body weight had stabilized at its full adult value. All animals were housed in
maximum groups of 5 in individually-ventilated cages in a temperature and humidity-controlled
environment with the exception of the mice in the drinking paradigm, which were housed singly
for the duration of their participation in the test. The animal housing rooms were maintained on
a 12 hr reverse light cycle. For activities that needed to be performed during the dark cycle, red
light filters were used to minimize the impact on circadian rhythms. Animals were given adlibitum access to water and solid food continuously except during the brief periods during which
behavioral measures were conducted.
Flow Cytometry
For CD5 expression analysis in the wild type and CD5 knockout mice, single cell
suspensions of CD4+ T cells from CD5KO and WT C57/BL6 mice spleens were purified using a
positive selection CD4+ T cell isolation kit (Miltenyi Biotec). Purified CD4+ T cells were then
stained with anti-CD5-PE (12±0051; eBioscience) and anti-CD4-APC (17±0041; eBioscience)
and CD5 surface expression was analyzed via flow cytometer (BD Accurri C6).
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Locomotor Activity
Locomotor activity was measured using an open field behavioral paradigm. Prior to the
test, an intraperitoneal (IP) injection of saline or EtOH (0.5 - 2.0 g/kg body weight) was
administered using a sterile needle. For all IP EtOH injections, a 16% (w/v) EtOH solution
filtered at 0.2 µm was utilized. For all saline injections, a 0.9% NaCl solution filtered at 0.2 µm
was utilized. Animals were injected without the use of anesthesia to prevent the introduction of
confounding variables. Immediately following the injection, the mouse was placed into an open
field where its movement in the chamber was recorded for 30 min using an infrared (IR) video
surveillance camera (Night Owl NI-103A-I-TD camera, VITEK VTQ-B01 B/W Quad Processor,
Pinnacle Studio Software). Total distance traveled during the session was then calculated using
Noldus Ethovision (Wageningen, the Netherlands) by tracing the path followed by the mouse
during this window of time. Saline was administered in the first session to establish a baseline
locomotor activity for each animal. Following two days of recovery, the EtOH sessions were
administered, starting at the lowest dose and progressing to the highest dose with two days
between each session. The percent baseline calculation was accomplished by dividing the
distance traveled during the respective EtOH trial by the distance traveled during the saline trial.
Loss of Righting Reflex
The loss of righting reflex (LORR) was measured following a sedating IP injection of
EtOH (4.0 g/kg). Following the injection, the mouse was placed on its back in a behavioral
chamber and observed and recorded through IR camera surveillance. After the mouse had
righted itself, it was removed and returned to its home cage. The video files were then scanned
manually to identify the time that the animal righted itself. This time was recorded, and the
duration of LORR was calculated by subtracting the time of injection from the time of righting.
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Two Bottle Choice Drinking
To measure EtOH consumption, a 24-hr access two bottle choice drinking paradigm was
used. Briefly, animals were separated into individual cages and given ad-libitum access to food
and two bottles, one containing water and the other containing 20% (w/v) EtOH for a period of
24 hr (190 proof EtOH, Decon Laboratories, Inc. Cat. No. UN1170). At the end of the 24-hr
window, the bottle containing the EtOH was removed and replaced by a second water bottle. On
the next day, one of the water bottles was again replaced by a bottle containing EtOH. This
pattern was repeated such that the animals had access to EtOH for a 24-hr period every other day
for 3 days per week. This pattern persisted for a total of three weeks of intermittent EtOH
access. Each time the EtOH bottle was added to the cage, the position was alternated to control
for intrinsic side preference. EtOH consumption was calculated on a pure EtOH per kg of body
weight.
Fast Scan Cyclic Voltammetry
To measure DA release dynamics, fast scan cyclic voltammetry (FSCV) was utilized
using a modification of methods previously published (Yorgason et al., 2020). Briefly, the
mouse was anesthetized by brief exposure to isoflurane and then quickly decapitated. The brain
was then rapidly extracted and placed in artificial cerebrospinal fluid (ACSF) containing (in
mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 2.4 CaCl2, 1.2 NaH2PO4, 21.4 NaHCO3, 11.1 D-Glucose
(NaCl, Fisher Chemical Cat. No. S271-3, KCl, Macron Fine Chemicals Cat. No. 6858-04,
MgCl2, VWR Cat. No. 0288-500G, CaCl2, Fisher Chemical Cat. No. C614-500, NaH2PO4,
Fisher BioReagents Cat. No. BP329-500, NaHCO3, Macron Fine Chemicals Cat. No. 7412-06,
D-Glucose, Fisher Chemical Cat. No. D16-3). The glutamate antagonist Ketamine (0.1 mg/mL)
was also added to the cutting solution to reduce excitotoxicity and thereby improve slice health
(Mylan, Cat. No. NDC 67457-001-00). The brain was sectioned at room temperature using a
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Leica vibratome (model VT 1200 S) to a thickness of 300 µm and incubated in ACSF
maintained at 35 °C until the end of the experiment. Recordings were made using carbon fiber
electrodes (7 μm diameter carbon fiber, Thornel T-650, Cytec). A strand of carbon fiber was
aspirated into a borosilicate glass capillary tube and then pulled on a vertical Narishige pipette
puller. The carbon fiber was then cut so that 100-150 µm was left protruding out the tip of the
electrode. When a DA signal with an appropriate voltammogram in the NAc was located,
baseline spontaneous DA currents were recorded. The rate of occurrence of these spontaneous
currents was then compared between groups. Demon Voltammetry Analysis Software (Wake
Forest Innovations) was used to collect and analyze the FSCV data (Yorgason et al., 2011).
Single-Unit Recordings
Single-unit recordings were performed in vivo under 1-2% isoflurane anesthesia (Fluriso,
VetOne, Cat. No. ADC 13985-528-60). Following brief anesthesia, the mouse was placed on a
clean temperature regulating pad and secured in place using ear bars. The scalp was opened and
an approximately 3 mm hole was drilled in the skull above the ventral tegmental area.
Recording electrodes were pulled using a vertical pipette puller (puller: Narishige Cat. No. PE-2,
capillary tubes: A-M Systems Cat. No. 603000) and the tips broken under microscopic control to
1-2 µm internal diameter and an impedance of 1-3 MOhm tested at 1000 Hz and filled with 1.0
M KCl (Macron Fine Chemicals Cat. No. 6858-04). Using stereotaxic manipulators, the
recording electrode was navigated to the VTA [from bregma: 2,900 µm anteroposterior (AP);
300 µm mediolateral (ML)]. The electrode was maneuvered from 3,700 µm to 5,200 µm
dorsoventral (DV), and the number of GABA neurons encountered and baseline firing rate for
each was recorded for the tract. This was then repeated for multiple tracts per animal prior to
recording transient GABA activity. Following the tract recordings, a stable GABA neuron was
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located with a firing rate of between 10-40 Hz and a recording of the discriminated spikes began.
Following stabilization of firing rate, an IP saline injection was administered. The behavior of
the neuron was recorded for 30 min and then an IP injection of EtOH (0.75 g/kg) was
administered. The neuron was then monitored for another 30 min prior to terminating the
experiment. At the conclusion of the experiment, the animals were humanely euthanized by
isoflurane overdose and cervical dislocation to confirm death.
Results
Knockout Characterization
The first imperative was to confirm that the knockout mouse was a valid model for a CD5
deficient organism. We accomplished this using flow cytometry. We observed that the CD5
population that was present in the C57 control group was notably absent in the CD5 KO group
(Fig. 1).

Figure 4-1: CD5 Knockout (KO) mice exhibit a lack of CD5 expression. A) Histogram
illustrating the number of particles counted that are CD5+ between the KO (left) and the
wildtype (right). B) Flow cytometry scatter diagrams illustrating the CD5+ population in wild
type (left) and CD5 KO (right) mice.
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Alcohol-Induced Sedation
Under typical circumstances, EtOH at low doses reduces locomotor activity, and at high
doses it induces ataxia and unconsciousness, both of which are manifestations of the sedative
properties of EtOH. To assess the sedative effects of EtOH in a CD5 deficient mouse
population, we measured locomotor activity and loss of righting reflex (LORR) in both C57 and
CD5 KO mice.
Locomotor activity following treatment with saline or EtOH (0.5 – 2.0 g/kg, IP) was
assessed using a mixed model ANOVA with genotype as a between-subjects factor and dose as a
within-subjects factor. Subjects were 15 mice (8 WT and 7 CD5 KO) who underwent all
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treatment conditions. Locomotor activity was normalized to the saline condition in each mouse.
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Figure 4-2: CD5 KO mice have lower baseline locomotor activity. (Top left) Representative
trace from a C57 saline run, (Top right) Representative trace from a CD5 KO saline run,
(Bottom) The baseline distance traveled compared between C57 and CD5 KO mice.
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The Greenhouse-Geisser correction for sphericity was applied to all within-subjects factors in
this analysis.
Prior to analysis all data were assessed for normality and outliers. The data were found to
be roughly normally distributed. One outlier was identified and fenced to the relevant limit. The
treated data was analyzed alongside the original untreated data. As there were no differences in
which terms were found to be significant between the two data sets and the effect size estimates
were nearly identical, we report only the results from the analysis of the untreated data. The
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results of the analysis of the treated data are available upon request.

WT
KO

120
100

*

80
60
40
0.5

1.0
1.5
EtOH (g/kg, IP)

2.0

2.5

Figure 4-3: CD5 KO mice have blunted EtOH reduction to locomotor activity. (Top left)
Representative tracing of a C57 2.0g/kg run, (Top right) Representative tracing of a CD5 KO
2.0g/kg run, (Bottom) Dose response curve showing the impact of EtOH on locomotor activity in
C57 and CD5 KO mice.
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We found that under baseline conditions CD5 KO mice exhibit significantly less
locomotor activity than their wild type counterparts (Fig. 2). Additionally, EtOH significantly
reduced locomotor activity in a dose dependent manner (Fig. 3; F(3,39) = 3.90, p = 0.018, partial
η2 = 0.23 [0.01, 0.39]). The reduction in locomotor activity occasioned by ethanol administration
was smaller in CD5 KO mice as compared with WT mice (Fig. 3; F(1, 13) = 10.18, p = 0.007,
partial η2 = 0.44 [0.04, 0.66]). The degree to which the EtOH mediated decrease in locomotor
activity was attenuated in CD5 KO mice was not dose dependent (Fig. 3; F(3, 39) = 2.86, p =
0.052).
When injected with a high dose of EtOH (4.0 g/kg), CD5 KO mice showed a
considerable trend toward a lower duration of LORR than the C57 controls, indicating a reduced
response to the sedating effects of EtOH in the CD5 KO population (Fig. 4). However, this
effect was not statistically significant, and as such, conclusions cannot yet be drawn based on
these data. Additional experiments are underway to validate this trend with a more appropriately
powered sample.
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Figure 4-4: CD5 KO mice show reduced EtOH sedation (Preliminary). Preliminary data
suggesting that CD5 mice exhibit a reduced loss of righting reflex with exposure to alcohol.
Effect is currently underpowered and therefore not statistically significant.
63

Ethanol Consumption
Perhaps of greatest importance was to understand the impact of CD5 on EtOH seeking
behavior. To measure this, we utilized a 24-hr access two-bottle choice drinking paradigm.
Ethanol consumption in this paradigm was assessed using a mixed model ANOVA with
genotype as a between-subjects factor and week as a within-subjects factor. Subjects were 12
mice (6 CD5 KO and 6 WT). Prior to analysis all data were assessed for normality and outliers
as described above. These data were found to be roughly normally distributed. One outlier was
identified and fenced to the relevant limit. The treated data were analyzed alongside the original
untreated data. There were no differences in which terms were found to be significant between
the two sets of data however it appeared that the effect size estimates were inflated by the outlier.
As such we are reporting the results from analysis of the treated data. The results from the
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analysis of the untreated data will be made available upon request.
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Figure 4-5: CD5 KO mice drink less ethanol than wildtype controls. (Left) CD5 KO mice
consistently drank less ethanol than WT mice over three weeks. (Right) Weekly averages for WT
and CD5 KO mouse ethanol consumption.
Ethanol consumption was lower in CD5 KO mice than in WT mice (Fig. 5; F(1, 10) = 9.64,
p = 0.011, partial η2 = 0.49 [0.03, 0.71]). Additionally, EtOH consumption increased in both
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groups over time (Figure 5. F(2, 17) = 4.99, p = 0.028, partial η2 = 0.37 [0.01, 0.58]). The increase
in EtOH consumption over time was not genotype dependent (Fig. 5; F(2, 17) = 0.64, p = 0.514).
Spontaneous Dopamine Release
We wanted to understand if these effects were mediated by DA release mechanisms, and
so we compared the spontaneous DA release between the knockout mice and the controls.
Spontaneous dopamine release events were measured in the slice preparation using FSCV.
Utilizing a simple Student’s T test, there was no difference observed between slices obtained
from CD5 KO mice and slices obtained from C57 mice (Fig. 6; p > 0.05).

DA Spon Frequency (Hz)

2.0
1.5
1.0
0.5
0.0

WT

KO

Figure 4-6: CD5 KO mice do not differ from WT controls on spontaneous DA release. CD5 KO
mice do not exhibit altered frequency of spontaneous DA release in the NAc under baseline
conditions.
Ethanol Effects on VTA GABA Neurons in CD5 KO Mice
Baseline firing rate data from 312 neurons recorded from 39 mice (see Table 1 for
complete breakdown) were analyzed using a two-way analysis of variance (ANOVA) with sex
and genotype as between subject factors.
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Genotype

Sex

# Mice

# Tracts

# Neurons

Female

9

27

72

Male

14

42

88

Female

7

21

79

Male

9

27

73

C57 WT

CD5 KO

Table 1: Breakdown of the number of animals, tracts, and neurons recorded by group.
Post-hoc tests with a Bonferroni correction were performed following detection of a
significant interaction term. Prior to analysis, data were assessed for outliers and normality using
the interquartile range (IQR) rule and the Shapiro-Wilk test, respectively. The data were found to
be non-normally distributed. Tukey’s ladder indicated that applying a log transformation to the
data would result in a normal distribution. As such a set of transformed data was created where a
log transform was applied and the outliers (3% of all data) were fenced to the relevant limit
(median ± 1.5 IQR). These data were analyzed alongside the original untransformed data. As
there were no differences in which terms were found to be significant between the two data sets
and the effect sizes were comparable (slightly smaller in the untransformed data set) we report
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only the results from the analysis of the untransformed data. The results of the analysis of the
transformed data are available upon request.
The baseline firing rate of VTA GABA neurons was found to be higher in female mice
than in male mice (Fig. 7; F(1, 308) = 23.98, p < 0.001, partial η2 = 0.07 [0.03, 0.13]). There was
not a significant effect of knockout of CD5 on baseline VTA GABA neuron firing rate (Fig. 7;
F(1, 308) = 2.51, p = 0.114). There was, however, a significant interaction between sex and
genotype (Fig. 7. F(1, 308) = 5.53, p = 0.019, partial η2 = 0.02 [0.00, 0.06]). This significant
interaction was likely due to the reduction in the baseline firing rate of VTA GABA neurons in
CD5 KO females (t = 2.74, p = 0.012) but not CD5 KO males (t = 0.55, p = 1.000), relative to
their sex-matched WT controls.
The peak reduction in VTA GABA neuron firing rate following EtOH administration was
analyzed across 31 mice (n by group: female/WT = 6; female/KO = 6; male/WT = 11; male/KO
= 8) using a two-way ANOVA with sex and genotype as between subject factors. Data were
assessed for outliers and normality as stated previously. Data were found to be relatively normal
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Figure 4-7: CD5 KO mice do not differ from WT controls in basal firing rate or EtOH
dependent firing rate reduction. (Left) Baseline firing rate for GABA neurons. (Right) The peak
reduction of firing rate induced by a 0.75g/kg intraperitoneal injection of EtOH.
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and no outliers were detected. The firing rate of VTA GABA neurons following EtOH
administration was not significantly affected by sex (Fig. 7; F(1, 27) = 0.29, p = 0.595), genotype
(Fig. 7; F(1, 27) = 0.03, p = 0.875), or sex by genotype interaction (Fig.7; F(1, 27) = 2.04, p =
0.165).
Discussion
Alcohol-Induced Sedation
Alcohol has various effects on motor function and consciousness. In humans and in mice
it is well known to cause ataxia, sedation, and unconsciousness at high doses. However, at
present there is still much to be learned about the exact mechanism by which these and other
symptoms occur. We observed that a genetic knockout of the T cell marker CD5 blunted some
of EtOH’s sedative effects, namely the reduction in locomotor activity and the loss of the
righting reflex (preliminary). We also observed that the wild type mice exhibited greater
locomotor behavior prior to any EtOH exposure. It is possible that the effect we observe in the
blunting of the effect of EtOH-induced sedation is related to the differences in baseline activity.
After exposure to EtOH, the raw distance traveled scores between the two genotypes were very
similar (data not shown). It seems possible that we are observing somewhat of a floor effect with
the CD5 KO mice where they began with low locomotor activity and did not get any lower with
EtOH exposure while the WT controls began with very high locomotor activity that decreased
with exposure to EtOH.
In addition to a mitigated effect of EtOH sedation, we also observed a shift in number of
visits to the center region. The wild type controls again had a high number of visits to the center
region on average, which reduced with exposure to EtOH while the CD5 KO mice began with a
low number of visits and stayed low. The subjective observation that this trend mirrors the trend
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observed in overall distance traveled hints faintly that there could be a causal relationship
between these parameters. This becomes more clear when we look at the time spent in the center
region. There was no difference between strains in the time spent in the center region, and both
strains saw a decrease in time spent in the center region when they were exposed to EtOH. This
means for the C57s that had a high number of visits to center that their visits must have been
shorter in order to have more visits in the same amount of time. It is worth noting at this point
that some of the CD5 KO mice exhibited the qualitative trait of stopping periodically in the
center of the chamber. While the cause of this stopping behavior is unknown, it could be the
cause of CD5 KO mice having fewer visits to the center but spending the same amount of time
there.
While the loss of righting reflex did not reveal a statistically significant difference
between genotypes, it seems evident that there is a clear trend present that could be verified with
a properly powered sample. Therefore, additional experiments are underway to supplement this
preliminary finding and evaluate whether this effect is real or happenstance. If we assume that
the trend is supported by the results from the current experiments, this would provide parallel
evidence that CD5 KO mice exhibit resistance to the sedative effects of EtOH.
Ethanol Consumption
There are very few treatments currently approved to treat AUD, and the treatments that
do exist have mixed efficacy. It is therefore essential to continue to elucidate factors that impact
EtOH seeking behavior. We decided to evaluate the differences between the CD5 KO and WT
mice in regards to EtOH drinking behavior and found that CD5 KO mice drink less EtOH in a
24hr access two-bottle choice paradigm. This pattern was persistent throughout the entire 21-day
testing period.
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We have investigated the role of IL-10 in DA dynamics and found that while IL-10 was
not intrinsically rewarding in a conditioned place preference paradigm, it does directly increase
the firing rate of DA neurons in the VTA and increase DA release in the NAc (data not
published). It has been shown that B cells that are CD5+ express more IL-10 than cells that are
CD5- (Gary-Gouy et al., 2002). It may be that IL-10 secretions from CD5+ B cells occur in
response to EtOH and mediate some of the reinforcing properties of EtOH. This could explain
why CD5 KO mice exhibit reduced EtOH consumption behavior as compared to their WT
counterparts. Future experiments will need to be conducted to validate this model.
Ethanol Effects on GABA Neuron Inhibition
We have repeatedly reported that EtOH acutely inhibits GABA neuron firing rate at
physiologically-relevant levels (Gallegos et al., 1999; Ludlow et al., 2009; Steffensen et al.,
2009; Stobbs et al., 2004). We anticipated that CD5 KO mice would exhibit reduced inhibition
to EtOH in this same measure. However, we observed that there were no baseline differences in
GABA neuron firing rate between CD5 KO mice vs WT mice and likewise that both genotypes
are equally affected by a 0.75 g/kg IP injection of EtOH. This was initially surprising given the
differences in EtOH consumption and sedation that we observed. It is possible that the effects
we observe elsewhere are mediated by direct activity onto DA neurons rather than indirect
activity on GABA neurons. In future work we will measure DA neuron activity to evaluate this
hypothesis.
We also observed a sex difference between the average baseline firing rate of GABA
neurons in C57 WT mice, which was not seen in the CD5 KO mouse. Because the WT mice
were not the focus of this study, we did not follow this up with additional experiments, but it
could be worth exploring in a future study design.
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Taken together, these results suggest that CD5 plays a role in the sedative effects of
EtOH as well as EtOH consumption. Considering the tremendous need for new and improved
treatments for alcohol use disorder, the latter will be the focus of future work and could result in
the discovery of a novel treatment target for AUD.
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Abstract
Dopamine (DA) transmission is a key player for the reinforcing properties of various
drugs of abuse. The current dogma is that DA transmission is increased via the inhibition of
ventral tegmental area (VTA) GABA neurons and that excitation of VTA GABA neurons results
in decreased DA transmission. Microglia, the major neuroimmune effector in the brain, may be a
key mediator in this process by releasing cytokines following activation. We used standard cellattached and whole cell mode electrophysiological techniques to evaluate the effects of select
cytokines on VTA neuron firing rate in vitro. We found no change in firing rate in VTA DA or
GABA neurons in response to IL-6, but an increase in firing rate in VTA DA neurons response
to IL-10. Consistent with the changes in firing rate, optically evoked IPSCs were found to be
decreased in response to IL-10, and mIPSCs were found to be decreased in amplitude. Ex vivo
voltammetry and in vivo microdialysis were performed to determine whether IL-10 can directly
result in an increase in DA release. Although ex vivo voltammetry showed no change in DA
release, IL-10 increased DA release in vivo. Intra- cisterna magna IL-10 administration produced
conditioned place aversion. These findings suggest that cytokines such as IL-10 may play a role
in the reinforcing properties of drugs of abuse.
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Introduction
The mesolimbic dopamine (DA) system originates in the midbrain ventral tegmental area
(VTA) and projects to the nucleus accumbens (NAc) area of the striatum. This system is
involved in motivation and the reinforcement of behaviors (Wise, 2008). Current dogma
maintains that addiction is based on the dysregulation of the mesolimbic DA system. Ventral
tegmental area DA neurons are regulated by inhibitory γ-aminobutyric acid (GABA) neurons
found locally in the VTA and in other brain areas. Drugs of abuse such as alcohol and opioids
alter GABAergic transmission onto DA neurons, providing evidence that they play a critical role
in the rewarding properties of drugs (Bonci & Williams, 1997; Gallegos et al., 1999; Theile et
al., 2011).
Neuroimmune mechanisms may underlie some of the intoxicating, rewarding, and
neuroadaptive effects of drugs of abuse. Mice administered lipopolysaccharide (LPS), a bacterial
signal that triggers immune system activation, show decreased firing in VTA DA neurons
(Blednov et al., 2011) and increased DA release in the NAc in vivo (Borowski et al., 1998).
These findings suggest that neuroimmune activation alters the mesolimbic DA system and could
contribute to the pathology of addiction.
To date, only a few studies have evaluated the effects of cytokines on VTA neurons, and
none has addressed cytokine effects on VTA GABA neurons. Although no studies have tested
the effects of cytokines on VTA neurons, the anti-inflammatory cytokine interleukin (IL)-10 has
been shown to reduce GABA inhibition in the hippocampus (Suryanarayanan et al., 2016). Thus,
IL-10 is a likely mediator of the effects of drugs of abuse on GABA synaptic transmission in
VTA neurons and subsequent DA release. In the current study, we investigated the effects of IL10 on VTA neuron firing rate and GABA transmission on VTA DA neurons. We also evaluated
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IL-10 effects on DA release in the NAc and in the conditioned place preference (CPP) procedure.
We hypothesized that IL-10 would inhibit GABA synaptic transmission on VTA DA neurons
and increase DA release in the NAc, and exhibit rewarding properties.
Methods
Animal Subjects
Male C57BL6 (black) mice, VGAT-ChR2-EYFP mice, and glutamate-decarboxylase-67
(GAD-67)-green fluorescent protein (GFP) knock-in (GAD67-GFP) on a CD-1 (white albino)
mouse (Tamamaki et al., 2003) were bred and cared for in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals. For each methodology to
be employed, animals were treated in strict accordance with the Brigham Young University
Animal Research Committee (IACUC) guidelines, which incorporate and exceed current NIH
guidelines. Once weaned at PND 21, all mice were housed in maximum groups of five and given
ad libitum access to water and solid food and placed on a reverse light/dark cycle with lights ON
from 10 PM to 10 AM.
Preparation of Brain Slices
All brain slice preparations were performed in P28-60 day old C57BL/6-ChR2-VGAT
and GAD67-GFP knock-in mice. Brains were extracted following brief isoflurane anesthesia
(5%). Upon extraction, the brain was secured onto a cutting stage using a cyanoacrylate
adhesive. The brain was then sectioned in artificial cerebral spinal fluid (ACSF; in mM: 126
NaCl, 11.1 Glucose, 2.5 KCl, 1.2 NaH2PO4, 21.4 NaHCO3, 1.2 MgCl2, 2.4 CaCl2) bubbled with
carbogen, comprised of 95% O2 and 5% CO2. Targeting the VTA, horizontal slices (220 μM
thick) were then placed in an incubation chamber containing ACSF supplied with carbogen for at
least 30 min. After 30 min, brain slices were then placed in a recording tissue chamber with
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ACSF continuously flowing at physiological temperature (35 °C). Cytokines were reconstituted
and frozen in aliquots until ready to use: IL-10 (20 ng/ml, Peprotech), IL-6 (300 ng/ml,
BioLegend).
Electrophysiology Recordings in Brain Slices
Electrophysiology studies used electrodes pulled from borosilicate glass capillaries (2.5-6
MΩ) and then filled with one of four solutions: an ACSF solution previously described, a
potassium-gluconate pipette solution [in mM: 123 K-gluconate, 0.2 EGTA, 10 HEPES, 8 NaCl,
2 Mg-ATP, 2 Na3-GTP] for studies investigating optogenetically-evoked inhibitory postsynaptic currents (oIPSC) or miniature IPSCs (mIPSC), or a K-gluconate solution spiked with a
phosphoinositide 3-kinase (PI3K) inhibitor (LY294002, Cayman Chemical, Item #: 70920) or its
inactive structural homolog (LY303511, Cayman Chemical, Item #: 15514). Pipettes having tip
resistances of 2.5 – 5 MΩ, and series resistances typically ranging from 7 to 15 MΩ were used.
Positive pressure was applied to the electrode when approaching the neuron. For cell-attached
recordings, a seal (10 MΩ – 1 GΩ) was created between the cell membrane and the recording
pipette by applying suction to the electrode. Spontaneous spike activity was then recorded in
voltage-clamp mode with an Axon Instruments Multiclamp 700B amplifier and sampled at 10
kHz using an Axon 1440A digitizer and collected and analyzed using pClamp10 software. A
stable baseline recording of firing activity was obtained for 5-10 min before adding any
substances. Whole cell voltage clamp recordings were filtered at 2 kHz with an Axon Instruments
Multiclamp 700B amplifier and digitized at 5 to 20 kHz respectively using an Axon 1440A
digitizer. Axon Instruments pClamp ver10, Mini Analysis (Synaptosoft: Decatur, GA), and Igor
Pro (Wavemetrics: Oswego, OR) software packages were utilized for data collection and
analysis. A 470 nm blue light was used to evoke oIPSCs in VGAT-ChR2-EYFP mice. Using a
paired-pulse stimulus, the stimulation was adjusted to a half-max level in order to allow the
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measurement of changes that increase or decrease oIPSC levels. For experiments where boiled
IL-10 was used, the solution containing the IL-10 was placed in a microcentrifuge tube and
submerged in boiling water for at least 1 min. Recordings of mIPSCs and oIPSCs were done in
the presence of 3 mM kynurenic acid (Sigma, Cat. No. K3375) and 500 µM lidocaine (Sigma,
Cat. No. L5647) to block glutamatergic excitatory synaptic input.
Ex Vivo Voltammetry
Slices were prepared as previously described, transferred to the recording chamber, and
perfused with ACSF (34 °C) at a rate of ∼1.8 ml/min. Fast scan cyclic voltammetry recordings

were performed and analyzed using Demon Voltammetry and Analysis software (Yorgason et

al., 2011) (RRID:SCR_014468). The carbon fiber electrodes used in voltammetry experiments
were made in-house. To make these electrodes, the carbon fiber (7 μm diameter, Thornel T-650,
Cytec) was aspirated into a borosilicate glass capillary tube (TW150, World Precision
Instruments). Electrodes were then pulled on a P-87 Horizontal pipette puller (Sutter
Instruments) and cut so that 100–150 μm of carbon fiber protruded from the tip of the glass. The
electrode potential was linearly scanned as a triangular waveform from −0.4 to 1.2 V and back to
−0.4 V (Ag vs AgCl) with a scan rate of 400 V/s (Yorgason et al., 2011). Before inserting the
carbon fiber electrode into the brain slice, the voltage ramp was applied every 16 msec (60 Hz)
for a 5–10 min period. After this electrode conditioning period, the scanning interval was
changed to 100 msec (10 Hz). If electrodes had low electrical noise (median SD < 0.07 nA
averaged across six 1 s bins), then they were used for experiments. Carbon fibers were advanced
completely into the tissue at a 20° angle with the tip positioned ∼85 μm below the slice surface.
Dopamine release was evoked through electrical stimulation (1 pulse/min) via a glass
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micropipette (30 μA, monophasic+, 0.5 ms). Paired pulse stimulations were performed with
interstimulus intervals of 0.5, 1, 2, 4, 8, 12, and 16 Hz.
Microdialysis and High-Performance Liquid Chromatography
These experiments were conducted in 8 mice per treatment condition. A microdialysis
probe (CMA 7, Harvard Apparatus, Holliston, MA, USA) was stereotaxically inserted into the
nucleus accumbens (NAc) at the following coordinates (relative to bregma): +1.5 anteroposterior
(AP), ±0.6 mediolateral (ML), -5.0 dorsoventral (DV). Artificial cerebrospinal fluid was
perfused through the probe at a rate of 2.0 µl/min. Samples were collected every 20 min for a
baseline period of at least 2 hr. Once a stable baseline was established, an intracerebroventricular
microinjection of 60 ng of IL-10 in 1 µl of ACSF or 1 µl of ACSF alone was administered. The
microinjection was carried out using a 10 µL Hamilton syringe (Reno, NV, USA) with a 25
gauge needle in conjunction with a microsyringe pump injector (UMP3, World Precision
Instruments [WPI], Sarasota, FL, USA) attached to a microdrive controller (Micro4, WPI). The
coordinates for the microinjection were as follows: -0.5 AP, ±1.1 ML, -2.4 DV. Microdialysis
sampling continued for an additional 2 hr following the microinjection. All mice were
anesthetized for the duration of the procedure using isoflurane (1.2% - 1.8%). Determination of
the dopamine (DA) concentration in the microdialysis samples was performed using a highperformance liquid chromatography (HPLC) system (Ultimate 3000, Thermo Fisher Scientific,
Waltham, MA, USA) coupled to an electrochemical detector (Coulochem III, ESA). The
electrochemical detector included a guard cell (5020, ESA) set at +275 mV, a screen electrode
(5014B, ESA) set at -100 mV, and a detection electrode (5014B, ESA) set at +220 mV.
Dopamine was separated using a C18 reverse phase column (HR-80, Thermo Fisher Scientific).
Mobile phase containing 75 mM H2NaO4P, 1.7 mM sodium octane sulfonate, 25 µM
ethylenediaminetetraacetic acid, 0.714 mM trimethylamine, and 10% acetonitrile was pumped
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through the system at a flow rate of 0.5 ml/min. Dopamine levels following the microinjection
were expressed as percentage of baseline, with the baseline being determined by the average DA
concentrations of 3 consecutive stable collections occurring prior to the microinjection. The first
hour of microdialysis data on DA release in the NAc was analyzed using a mixed model analysis
of variance (ANOVA) with time as a within-subjects factor, treatment condition as a betweensubjects factor, and a time by treatment condition interaction term. A Greenhouse-Geisser
correction for sphericity was applied to the results of the ANOVA. Prior to analysis, the data
were checked for outliers (classified as a datum falling ±2 interquartile ranges [IQR] beyond the
median). Two data points were identified as outliers using this method. These outliers were
subsequently fenced to the upper limit of the outlier test (median + 2 IQR) as we did not find any
evidence of data input error or variation from experimental protocol that would have justified the
removal of these data points. The data were also found to be relatively normal using the ShapiroWilk test.
Conditioned Place Preference Procedure
Conditioned place preference (CPP) procedure experiments were carried out in 10 mice
per treatment condition. Place conditioning occurred in a 16” x 16” x 16” apparatus constructed
out of Plexiglass. The floor of the apparatus was divided into an 8” x 16” rough compartment
and an 8” x 16” smooth compartment on testing days by the insertion of a 1/8” thick piece of
textured acrylic. During conditioning days, the insertion or removal of a 16” x 16” piece of
textured acrylic allowed pairing of the different treatment conditions with the different contexts.
The CPP procedure consisted of 3 phases: pretest, conditioning, and posttest. The pretest and
posttest phases occurred over one day each with each mouse placed into the apparatus and
allowed to choose between the two contexts for 30 minutes. The pre-test and post-test sessions
occurred prior to beginning and after completion of the conditioning trials, respectively. The
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conditioning trials occurred over the course of three days. Each day the mice were lightly
anesthetized with isoflurane (3%) and given an intra-cisterna magna (ICM) injection of ACSF (1
µl) in the morning and an ICM injection of IL-10 (60 ng in 1 µl ACSF) or vehicle (1 µl ACSF)
in the afternoon. Immediately following the injections, the mice were transported to the CPP
apparatus and placed in the smooth compartment (after an ACSF injection) or the rough
compartment (after an IL-10 injection) after waking up from the anesthesia. The mice were left
in the compartment for 10 min for each conditioning trial. The apparatus has been found to be
biased, with the mice showing an initial preference for the smooth compartment. The time spent
in the IL-10 or vehicle paired chamber was analyzed using a mixed models ANOVA with
treatment condition as a between-subjects factor, test (pre or post) as a within-subjects factor,
and treatment condition by test as an interaction term. A Greenhouse-Geisser correction for
sphericity was applied to the results of the ANOVA. Data were cleaned as described in the
microdialysis and high-performance liquid chromatography section. One datum was identified as
an outlier and bounded to the median + 2 IQR limit for outlier detection. The data were found to
be relatively normal using the Shapiro-Wilk test.
Statistical Analyses
All results are presented as raw mean values and percent control ± SEM. Results before
and after drug exposure were compared using a two-tailed paired t-test. Experiments relying on
variance in time or current were analyzed using an ANOVA with post hoc t-test at individual
points. Statistical significance required ≥ 95% level of confidence (P≤0.05). Analysis software
included Microsoft Excel, STATA, and Igor Pro (Wavemetrics, Oswego, OR). Significance
levels are indicated on graphs with asterisks *,**,*** and correspond to significance levels
P<0.05, 0.01 and 0.001, respectively. Figures were constructed with Igor Pro software.
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Results
IL-10 Modulates the Firing Rate of VTA Neurons
We tested the effects of select cytokines (IL-6 and IL-10) on VTA DA and GABA
neuron firing rates in cell-attached mode, which is a stable recording technique that does not alter
the intracellular milieu. We found that the anti-inflammatory cytokine IL-10 increased the firing
rate of VTA DA neurons by 70.63 ± 20.87% (Fig. 1; n=13, p=0.0204, by paired t-test), but had
no effect on the firing rate of VTA GABA neurons 0.63 ± 5.32% (Fig. 1; n=13; p=0.4476).
Interleukin-6, a pro-inflammatory cytokine, did not have any effect on firing rate of VTA GABA
or DA neurons (Fig. 2; DA: 113.98 ± 9.48%; n=4, p=0.3349; Fig. 2; GABA: 1.17 ± 11.24%;
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Figure 5-1: Effects of IL-10 on VTA Neuron Firing Rate. (Top left) Representative trace of the
effects of IL-10 on the firing rate of a DA neuron. (Top right) IL-10 increased VTA DA neuron
firing rate. (Bottom left) Representative trace of the effects of IL-10 on the firing rate of a GABA
neuron. (Bottom right) IL-10 had no effect on VTA GABA neuron firing rate.
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n=5; p=0.9061). These results suggest that IL-10 is modulating the firing rate of VTA DA
neurons by an alternative mechanism than by changing the firing rate of VTA GABA neurons.
As IL-6 did not significantly alter firing rate, it suggests that the effect of increasing firing rate is
specific to IL-10, or perhaps it is an effect specific to anti-inflammatory cytokines.
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Figure 5-2: Effects of IL-6 on VTA Neuron Firing Rate. (Top left) Representative trace of the
effects of IL-6 on the firing rate of a DA neuron. (Top right) IL-6 had no effect on VTA DA
neuron firing rate. (Bottom left) Representative trace of the effects of IL-6 on the firing rate of a
GABA neuron. (Bottom right) IL-6 had no effect on VTA GABA neuron firing rate.
Effects of IL-10 on Optogenetically-Evoked IPSCs on VTA DA Neurons
Based on the findings that IL-10 increased DA neuron firing rate, we tested the effects of
IL-10 on oIPSCs in DA neurons. Previous studies have shown that IL-10 inhibits GABAergic
synaptic inhibition in the hippocampus (Suryanarayanan et al., 2016), suggesting that IL-10 may
be acting through a similar mechanism to increase VTA DA neuron firing rate. We used
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channelrhodopsin-2 (ChR2) vesicular GABA transporter (VGAT) mice to activate GABA
neurons and then recorded from DA neurons to study the effects of IL-10 on GABA transmission
on DA neurons. We found that IL-10 decreased the amplitude of the oIPSC on DA neurons by
21.69 ± 6.31 % (Fig. 3; n=10; p=0.0397). This suggests that IL-10 may contribute to the
disinhibition of DA neurons by attenuating GABAergic synaptic transmission on VTA DA
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Figure 5-3: Effects of IL-10 on Optogenetic IPSCs on VTA DA Neurons. (Left) Representative
trace of the effects of IL-10 on the optogenetically-evoked IPSC in a VTA DA neuron. This
neuron had an IPSC that was decreased from 340pA to 190pA during IL-10 perfusion. (Right)
IL-10 decreased the amplitude of oIPSCs in 9 out of 10 neurons.
Effects of IL-10 on mIPSCs on VTA DA Neurons
In order to understand how IL-10 was affecting GABAergic synaptic release, we tested
the effects of IL-10 (10 pg/ml, 20 pg/ml and 40 pg/ml) on mIPSCs on VTA DA neurons, which
were recorded in the presence of ? to block action-potential mediated IPSCs. We found that IL10 did not affect the frequency of mIPSCs (Fig. 4; n=7) although there was a decreasing trend.
However, IL-10 significantly decreased the amplitude of mIPSCs in a dose-dependent manner
(Fig. 4; n=7). This effect was blocked by boiling the IL-10, confirming that it is the intact
cytokine that is causing the effect (Fig. 4; n=3). These results suggest that IL-10 has postsynaptic effects on GABAergic synaptic transmission on VTA DA neurons.
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Figure 5-4: Effect of IL-10 on mIPSCs in VTA DA Neurons. (Top left) IL-10 decreased the
amplitude of mIPSCs on VTA DA Neurons. (Top right) IL-10 had no significant effect on the
frequency of mIPSCs on VTA DA neurons. (Bottom) Boiling IL-10 eliminates its reduction in
mIPSCs in VTA DA neurons.

PI3K Inhibitor Blocks IL-10 Effects
To evaluate the mechanism by which IL-10 elicits these effects, we measured the
amplitude of mIPSCs in the presence of the PI3K inhibitor LY294002 (10 µM). Preliminary
data indicate that having LY294002 in the pipette during the measurement of mIPSCs may block
and possible even reverse the inhibitory effects of IL-10 on mIPSC amplitude (data not shown).
Additional experiments will confirm this.
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Effects of IL-10 on DA Release in the NAc
Based on previous evidence of increased DA neuron firing and decreased GABAergic
synaptic inhibition, the next question was whether DA release in the NAc is influenced by IL-10.
Therefore, we tested the effects of IL-10 on ex vivo evoked DA release in the core of the NAc. A
paired-pulse protocol of evoked DA release was used to determine if the interstimulus interval
combined with IL-10 had an effect on DA release (Fig. 5). From this data, a subtraction was
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Figure 5-5: Effects of IL-10 on Evoked DA Release in the NAc Ex Vivo Using Fast Scan Cyclic
Voltammetry. A paired-pulse ratio protocol was tested and then repeated with the superfusion of
IL-10. There was no significant difference between the control and IL-10 at any of the
stimulation intervals.
performed (data not shown) to determine whether IL-10 had an effect on evoked DA release. In
slices containing NAc terminals, without connections to the cell bodies in the VTA, IL-10 had no
effect on evoked DA release. Additionally, there was no interstimulus interval where a
significant difference was seen between control and IL-10. This suggests that IL-10 has no effect
on DA neuron terminals in the NAc. Dopamine release was also measured in vivo by
microdialysis following an intracerebroventricular (ICV) injection of IL-10 (60 ng/mouse).
Intracerebroventricular microinjections of IL-10 were found to modestly enhance DA release in
the NAc during the first hour following the microinjection (Fig. 6; F(1,14) = 10.97, p = 0.005; η2p
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= 0.439). Comparisons of individual timepoints during the first hr using t-tests revealed that DA
release in the NAc was enhanced specifically at 20 (t(14) = -2.903, p = 0.005) and 40 (t(13) = 2.589, p = 0.011) minutes post-microinjection. Based on the ex vivo DA release data above, only
the first hr of the microdialysis data was analyzed. There was not a significant effect of time
(F(3,41) = 1.12, p = 0.347) or a time-by-treatment condition interaction on DA release (F(3, 41) =
2.08, p = 0.135).

Figure 5-6: Microinjections of IL-10 enhance DA release in the NAc. Microinjections of IL-10
(60 ng, ICV) moderately enhance DA release in the NAc at 20 and 40 minutes after the
microinjection. Microinjections of vehicle (1 µl aCSF, ICV) failed to enhance DA release in the
NAc. * denotes significance level p < 0.05.
Effects of IL-10 on Conditioned Place Preference
Intra-cisterna magna injections of IL-10 were found to produce a conditioned place
aversion (Fig. 7; F(1,18) = 6.21, p = 0.023’ η2p = 0.256) as evidenced by decreased time spent in
the IL-10/vehicle paired chamber by IL-10-treated mice as compared with vehicle-treated mice
at the posttest (t(17) = 2.718, p = 0.015) but not at the pretest (t(18) = 0.7334, p = 0.473). This
finding was inconsistent with our hypothesis that ICM injections of IL-10 would be reinforcing.
Given that the apparatus has been found to be biased we may have encountered a floor effect on
the aversive properties of the IL-10 injection.
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Figure 5-7: ICM administration of IL-10 produced conditioned place aversion. IL-10
administration (60 ng, ICV) produced a conditioned place aversion. Avoidance of a chamber
paired with IL-10 administration was increased following the pairings as compared with a group
that received only vehicle pairings (1 µl aCSF, ICV) in the same chamber. * denotes significance
level p < 0.05.
Discussion
The purpose of this study was to investigate the effects of cytokines, particularly IL-10,
on VTA neurons to identify its potential role in modulating VTA neuronal activity, DA release,
and reward. Interleukin-10 modulates the firing of VTA DA neurons by decreasing GABAergic
synaptic inhibition onto VTA DA neurons. However, IL-6 had no effect on GABA or DA neuron
firing rate. We tested the effects of IL-10 on GABA synaptic transmission onto VTA DA
neurons and found that IL-10 inhibits GABAergic synaptic transmission. Our data also suggest
that IL-10 increases DA release in the NAc in vivo, although increased release is not seen in ex
vivo slice preparations. Surprisingly, IL-10 administration was not shown to be rewarding in the
CPP procedure,
Cytokine Effects on VTA Neuron Firing Rate
We observed that IL-10 increased the excitability of VTA DA, but not GABA neurons.
The increase in firing rate is consistent with the IL-10-dependent decrease in oIPSC and mIPSC
amplitude in VTA DA neurons, suggesting that decreased post-synaptic inhibition explains
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some, if not all, of the increased excitability of VTA DA neurons. Little is known about the role
of the anti-inflammatory cytokine IL-10 in the brain, particularly in regard to how it may be
involved in the response to ethanol and other drugs of abuse. Recent evidence has shown that IL10 inhibits mIPSCs in the hippocampus (Suryanarayanan et al., 2016). Interleukin-1β (IL-1β)
inhibits LTP induction, and this effect is prevented by IL-10 (Kelly et al., 2001).
We tested the effects of IL-6 on firing rate in order to compare pro-inflammatory vs antiinflammatory cytokines. No difference was observed on the firing rate of DA or GABA neurons,
although these results are not entirely conclusive due to the low sampling of neurons and the
abnormally high firing rate of the putative DA neurons. However, because no difference was
seen, we did not perform any further experiments with IL-6. Additional evidence suggests that
IL-6, a pro-inflammatory cytokine, may affect synaptic transmission. Interleukin-6 has been
shown to enhance excitatory postsynaptic potentials in the hippocampus (Nelson et al., 2012).
Additionally, overexpression of IL-6 alters the effects of acute ethanol on field excitatory
postsynaptic potentials and LTP (Hernandez et al., 2016).
Effects of IL-10 on Synaptic Transmission
GABAergic synaptic transmission was inhibited by IL-10. However, we did not test
whether glutamatergic (GLUergic) synaptic transmission is modified by IL-10. A recent study
showed that IL-10 modulates GLUergic synaptic activity in pyramidal neurons suggesting that
changes in GLUergic synaptic transmission may also be an important consideration in the VTA
(Nenov et al., 2019).
Activation of the IL-10 receptor (IL-10R) is mediated by the Jak/STAT pathway, and
leads to decreased cytokine production and decreased inflammation (Murray, 2006). Currently
the expression of IL-10 receptors in the brain is not well characterized. It has been shown that
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IL-10Rs are expressed in the brain on neurons in the hippocampus, cortex, and spinal cord as
well as microglia (Lim et al., 2013). It seems likely that IL-10Rs are expressed in the VTA as
well, but whether they are expressed on GABA or DA neurons or both, remains unknown. The
effects of IL-10 on GABA synaptic transmission could be due to activity on either presynaptic
GABA terminals or DA neurons. Recent evidence has shown that IL-10 inhibits GABAergic
synaptic transmission. For example, IL-10 inhibits both the frequency and amplitude of mini
IPSCs in the hippocampus, at least partially due to the postsynaptic effects of PI3K on
GABA(A)R expression (Suryanarayanan et al., 2016). It has also been shown that IL-10
modulates GLUergic synaptic plasticity. The induction of LTP is inhibited by IL-1β, and this
effect is prevented by IL-10 (Kelly et al., 2001). The lack of effect of IL-10 on VTA GABA
neurons, but inhibition of oIPSC and mIPSC amplitudes, but not mIPSC frequency, suggests a
post-synaptic effect on DA neurons.
IL-10 Increases DA Release
Increased VTA DA neuron firing logically results in increased DA release in the NAc.
Many drugs of abuse act in the VTA to cause increases in DA release in the NAc, such as
opioids, nicotine, and alcohol (Balfour, 2009; Deitrich et al., 1989; Fields & Margolis, 2015).
Our findings suggest that IL-10 (and perhaps other cytokines) may be mediating some of the
rewarding and reinforcing properties of drugs of abuse. Dopamine release is thought to correlate
with the reinforcement of behavior and conditioned preferences (Salamone & Correa, 2002;
Wise, 2008). In this study, we have shown that IL-10 increases DA release, which is suggestive
of reward. However, place conditioning found that IL-10 was aversive rather than rewarding.
Other studies have shown behavioral effects of anti-inflammatory cytokines on ethanol drinking
behaviors. For example, IL-10 in the basolateral amygdala decreased ethanol consumption, but
not sucrose consumption or performance in an open-field test (Marshall et al., 2017).
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Interestingly, another study found that antagonizing the IL-1 receptor in the basolateral amygdala
also decreased ethanol consumption (Marshall et al., 2016). These results suggest that antiinflammatory cytokines play a role in ethanol-related behaviors.
Our results affirm the importance of the neuroimmune system in mediating reward, and
particularly implicate IL-10 as a key mediator in these effects. Future studies are needed to
investigate the effects of other cytokines, particularly anti-inflammatory cytokines, in the
mesolimbic DA system in order to fully understand how cytokines may be involved in reward.
Additionally, more pharmacological research is needed to identify whether cytokines affect
GLUergic synaptic transmission in the VTA. Further research about IL-10’s modulation of DA
release will clarify the role of IL-10 in the neural circuitry of reward and could potentially lead to
novel pharmacological and behavioral treatments.
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CHAPTER 6: CONCLUSION
The field of alcohol research and treatment is in much need of advances, particularly
advances that will result in novel treatments or in the improvement of existing treatments. The
present work represents several discoveries that can help to advance alcohol research in support of
the development of novel treatments.
There are two pathways investigated here that, with additional research and validation,
could be utilized as novel drug targets for use in the treatment of alcohol use disorders with
potential to be effective in other substance abuse disorders. The first is the BDNF/TrkB/KCC2
pathway and the second is the CD5/IL-10 pathway.
Manuscript One
In the first manuscript we demonstrated that chronic alcohol exposure leads to a decrease
in sensitivity to the GABAA agonist muscimol. Under baseline conditions, muscimol decreases
the activity of VTA GABA neurons, but after chronic alcohol exposure this decrease is
mitigated. This difference is not seen in VTA DA neurons, indicating that GABA neurons and
DA neurons respond differentially to alcohol exposure as it pertains to the activity of GABAA
channels.
We also illustrated that DA neurons in the VTA are generally less sensitive to muscimol
than are VTA GABA neurons. Since GABAA channels are chloride dependent and GABAB
channels are potassium dependent, this could be due to the relative expression of GABAA vs.
GABAB receptors on DA neurons. In future experiments we may measure the relative
concentrations of GABAA and GABAB receptors on DA neurons to verify this hypothesis. We
could also use the GABAB blocker baclofen to produce a baclofen sensitivity curve and see if we
observe the same behavior that we observe with muscimol in response to chronic alcohol
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exposure. If we find a greater relative expression of GABAB receptors in DA neurons than in
GABA neurons, this could explain the differential response to muscimol we observed.
The reduction in sensitivity to muscimol’s inhibition we call GABA switching. It may be
that GABA switching is a result of a dysregulation of the chloride gradient, which we
investigated in our second manuscript.
Manuscript Two
In our second manuscript, we demonstrated that chronic exposure to alcohol causes an
increase in BDNF expression in the VTA and in the NAc with the more pronounced change in
the VTA. Although BDNF typically has preservative functions, we conclude that in this case it
is instigating a chain of events that in part leads to withdrawal symptoms and potentially
dependence as well. We tested the firing rate of VTA GABA neurons in the presence of BDNF
and found that there were no clear or obvious acute changes on the 5-30 minute time scale and
concluded that any impact BDNF was having on these neurons must be on a longer time scale.
To test longer time scales, we utilized the endogenous secretions of BDNF that occur during
withdrawal from chronic alcohol exposure.
Prior to chronic EtOH exposure, activating TrkB using the selective agonist 7,8-DHF
resulted in an increase in alcohol seeking and blocking TrkB resulted in a decrease in alcohol
seeking. This clearly illustrates the impact that activity at TrkB receptors can have on alcohol
drinking behavior. However, the clinical utility of this discovery is limited due to the results in
chronic EtOH exposed animals. The effect observed in the air exposed control mice was not
observed in the EtOH exposed animals, or, in other words, there was no difference in drinking
when TrkB was activated or blocked in the dependent animals. This could be due to adaptation
of TrkB receptors, which we may confirm in future experiments. Essentially, if TrkB is
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downregulated due increased exposure to its endogenous agonist, BDNF, this could readily
explain this reduced sensitivity to 7,8-DHF in the dependent animals.
Manuscript Three
In our third manuscript, we illustrated the importance of the T cell marker CD5 in the
sedative effects of alcohol. In an open field measure of locomotor activity, a CD5 KO
population of mice showed significantly less alcohol-induced sedation than wild type controls,
suggesting that CD5 is somehow important to producing the sedative effects of alcohol.
Additionally, in an LORR paradigm, a suggestive trend toward significance was observed.
Again, the CD5 KO mice appeared to be resistant to the sedating effects of alcohol at a higher
dose in that they recovered their righting reflex more quickly, although this trend was not
statistically significant with the current sample. Prior to publication, additional replicates of this
experiment will be run to confirm or deny the presence of a CD5-dependent effect on LORR.
We also demonstrated that the presence or absence of CD5 impacts alcohol seeking
behavior. In a 24-hour access two bottle choice drinking paradigm, the CD5 KO population
drank significantly less than the wild type controls. This is of critical importance, since a
decrease in drug seeking behavior can be an early indicator of a potential treatment target for
substance use disorders. However, considering the varied functions that CD5 has throughout the
body and immune system, it may prove to be an elusive drug target as it would likely produce an
array of unpleasant side effects. Additional work is needed elucidate the potential side effects of
acting on CD5 or its downstream effectors in an effort to reduce drug seeking behavior.
It should be noted that as with any study conducted in a knockout mouse, there must be
caution taken when interpreting results since knocking out certain genes from before birth can
result in adaptations elsewhere in the brain and body that could confound the results of the study.
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Correspondingly, future studies may include pharmacological agents that target CD5 and its
downstream effectors to validate the results obtained in this study. Future work may also include
additional studies investigating other differences in protein expression or behavioral traits
between CD5 KO mice and C57 wild type mice to ascertain what types of adaptations may have
occurred and whether they could be impacting the results obtained here.
Manuscript Four
In our fourth manuscript, we demonstrated that IL-10, which is secreted in greater
quantities by CD5+ B cells than CD5- B cells, has direct effects on DA neurotransmission. We
showed that IL-10 directly increased the firing rate of VTA DA neurons but not VTA GABA
neurons when perfused acutely. Concomitantly, we illustrated that IL-10 administered via ICV
injection increased DA release in the NAc as measured by microdialysis. These two findings
together would suggest that IL-10 administration would be intrinsically rewarding. However,
contrary to our expectations, we found that IL-10 was aversive when administered via
intracisternal magna injection in a conditioned place preference paradigm. We therefore
conclude that IL-10 influences DA neurotransmission but not in ways that are rewarding. It is
possible that this DA release could, however, still be reinforcing. For example, it has been
shown that painful stimuli can also cause an increase in DA release (Taylor et al., 2016). Indeed
it is crucial for the brain to be able to reinforce behaviors that lead to rewarding outcomes as well
as avoid behaviors that lead to hurtful outcomes, and so it stands to reason that painful stimuli
could also cause DA release which is critical for reinforcement mechanisms, both for the positive
and for the negative.
In summary, we conclude that these findings increase our understanding of how alcohol
elicits its effects on the brain and body, which understanding is crucial for the development of
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novel treatments and improvement of existing treatments for alcohol use disorder. We have
demonstrated two protein targets, TrkB and CD5, that appear to have influence on alcohol
seeking behavior, which suggests therapeutic potential, albeit not without the possibility of
significant side effects. Additionally, we have provided a framework for the discovery of a third
treatment target, KCC2, which has the potential for a therapeutic benefit with very few side
effects. Future work will focus on elucidating the therapeutic potential of KCC2 in substance
use disorders.
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